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ABSTRACT 
Public Health Relevance: The United States has 80 million employees with 
chronic pain resulting in annual losses of 61.2 billion dollars due to pain-related 
productive time lost. In addition, pain-related depression and inactivity reduce the quality 
of life. The development of effective analgesics is therefore important from a public 
health perspective. In this dissertation, the natural properties of herpes simplex virus 
(HSV-1) vectors are exploited to (i) develop an HSV-1 vector-based selection system that 
can potentially identify natural or chemical inhibitors of chronic pain and (ii) to test 
HSV-1 vector-expressed dominant negative PKCε (DNP) as a strategy to treat chronic 
pain. 
The vanilloid/capsaicin receptor (TRPV1) is a pro-nociceptive calcium ion 
channel that is upregulated in chronic pain. This occurs partly due to protein kinase C 
epsilon (PKCε)−mediated receptor phosphorylation. An HSV-1 vector expressing 
TRPV1 (vTT) was engineered and vTT-expressed TRPV1 functionality was confirmed. 
 iv
Treatment of vTT-infected cells with capsaicin or resiniferatoxin caused concentration-
dependent Ca+2 influx, leading to cell-death and a dramatic reduction in infectious particle  
yield. TRPV1 antagonists, ruthenium red and SB-366791 reversed agonist-induced cell-
death and rescued vTT growth, providing a basis for selection. Selection for antagonists 
was modeled using a mixed infection of vTT and vHG (capsaicin resistant control vector) 
and virus passage in the presence capsaicin. These experiments demonstrated that a 
single control vector particle was readily isolated from a population of 105 vTT particles. 
This approach can be used to identify antagonists from chemical or gene libraries and 
offers advantages of (i) a platform assay applicable to other ion channels and 
(ii) adaptability to high throughput formats. 
Dominant negative PKCε (DNP) was engineered into HSV-1 to create the vector, 
vHDNP. Following functional confirmation of vHDNP in U2OS, Vero cells and neurons, 
cobalt uptake showed a reduction of capsaicin sensitive vHDNP-transduced neurons. 
Electrophysiology confirmed this and also demonstrated a knockdown of TRPV1-
PKCε coupling in nociceptive neurons. In-vivo studies of noxious heat-induced 
nocisponsive behavior in vHDNP-inoculated rats showed a subtle inhibition of 
withdrawal responses when compared with controls. In conclusion, HSV-1 expressed 
dominant negative PKCε is a viable strategy to specifically inhibit TRPV1 function in 
order to treat chronic pain. 
 
 v
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1.0  BACKGROUND AND RATIONALE 
1.1 THE BIOLOGY OF PAIN AND NOCICEPTION 
1.1.1 Definition of pain and nociception.  
The philosopher and scientist, René Descrates first described pain in his treatise, 
Tractatus de Homine or the Treatise of Man published in 1664 as “the small rapidly moving 
particle of fire moves the skin of the affected spot causing a thin thread to be pulled. This opens a 
small valve in the brain and through it animal spirits are sent down to the muscles which 
withdraw the foot. Just as by pulling at one end of a rope one makes to strike at the same instant 
a bell which hangs at the other end.”  
Over 300 years since this first descriptive attempt, pain is currently viewed as a complex, 
evolutionarily conserved biological process, defined as “an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage, or described in terms of such 
damage” 1. While the sensation of pain encompasses emotion, the term nociception is used to 
describe the sensory component of pain. In order to apply an objective model for the study of 
pain, this dissertation, like most pain research is focused on nociception. 
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1.1.2 The nociceptive pathway. 
 Painful mechanical, inflammatory and heat stimuli directly activate distinct receptors 
expressed on the afferent terminals of specific dorsal root ganglion (DRG) neurons called 
nociceptors which are present in the epidermal and dermal layers of the skin. Following their 
activation, receptor-mediated nociceptive signaling cascades initiate generator potentials that in 
turn cause action potentials to propagate along the DRG axon. The consequent release of 
glutamate at central DRG afferent terminals in the superficial dorsal horn (SDH) of the spinal 
cord results in a progression of nociceptive currents along the second order axon to the thalamus. 
Nociceptive currents carried by second order neurons finally propagate to the cortex following a 
synapse with third order neurons in the thalamic nuclei. This results in the perception of pain at 
the level of the sensory cortex (Fig. 1).   
 Pain is subjected to extensive modulation at three levels that effectively form a complex 
regulatory matrix along the entire neuroanatomical axis of the nociceptive pathway 2. Fig. 1 
illustrates the nociceptive pathway and the levels of nociception, which are described below. 
1.1.3 Levels of nociception.  
 The quality of pain that is experienced results from complex and largely unknown 
interactions among cellular and anatomical components at three distinct levels of the nociceptive 
neuraxis. The following section describes these levels of regulation in some detail: 
i) At the peripheral level, nociceptive currents are triggered by ion channels and G-protein 
coupled receptors expressed within terminals of thinly myelinated Aδ and unmyelinated C 
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afferent fibers. These receptors directly sense inflammation and are regulated by complex 
intracellular signaling cascades. 
ii) The spinal level consists of SDH neurons that are subject to tonic inhibition by interneurons 
and descending cortical pathways. A quantitative balance between tonic inhibitory and excitatory 
currents thus decides whether or not nociceptive currents will successfully progress to the cortex. 
This is described as the gate control theory 3.  
iii) The supraspinal level integrates the emotional component of pain and consists of newly 
discovered, potentially regulatory pathways extending to the dorsolateral frontal lobes of the 
cortex or to the hypothalamus and amygdala. These cortical pathways may be responsible for the 
affective or emotional component of pain 4. 
Although relatively much is known about nociceptive regulation at the level of the SDH, 
regulatory mechanisms at peripheral and cortical levels are remain unknown. Recent research 
has led to the discovery of several new receptors and ion channels at the peripheral level of the 
nociceptive pathway 5. Activation mechanisms of many of these ion channels have been 
uncovered, however, gene products and signaling pathways that negatively regulate or modulate 
ion channel function are poorly understood. One reason for the lack of progress in this area arises 
from a dearth of tools to identify novel gene products and consequently, the signaling pathways 
that negatively modulate ion channel function. Chapter three of this dissertation focuses on the 
development of a novel method that can be adapted to screen chemical or cDNA libraries in 
order to identify novel inhibitors or modulatory gene products of these ion channels. 
 3 
  
Figure 1. The nociceptive pathway and levels of nociception.  
The nociceptive impulse travels from a peripheral pain source to the dorsal horn where, following 
a synapse, the current propagates along a second order neuron through midbrain structures and onto the 
thalamus. Third order neurons from the thalamus relay the nociceptive impulse to the somatosensory 
cortex. Additional modulatory inputs from the hypothalamus to the amygdala exist in the supraspinal 
region of the nociceptive pathway. Nociception is subject to modulation at peripheral, spinal and 
supraspinal levels of the nociceptive pathway. (Figure from DeLeo, Journal of bone and Joint Surgery, 
Vol 88-A, Suppl. 2, 2006)   
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1.1.4 Acute and chronic pain. 
 The pain response can be physiologically classified into acute and chronic phases. The 
pinprick is a typical example of the pain response displaying both these phases. Here, the 
pricking sensation or “acute first pain” is transmitted by thinly myelinated Aδ-fibers while the 
burning “chronic second pain” following the prick is transmitted by unmyelinated C-fibers of 
nociceptive DRG neurons 6. Fig. 2 shows a compound action potential recording in a peripheral 
nerve where conduction velocities for thickly myelinated Aβ and thinly myelinated Aδ-fibers are 
faster when compared with unmylelinated C-fibers. The acute pain response carried by Aδ-fibers 
is adaptive and necessary for withdrawal from painful stimuli, while chronic pain responses 
carried by unmyelinated C-fibers are maladaptive and therefore dispensable. The next sections 
will describe the pathophysiology of chronic pain and its consequent implications from a 
therapeutic standpoint. 
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Figure 2. The physiology of acute and chronic pain responses. 
 Panel a depicts the different peripheral afferent nerve fibers along with their respective 
sensory functions. Thickly myelinated Aα and Aβ fibers carry impulses coding for light touch and 
proprioception, while thinly myelinated Aδ and unmyelinated C-fibers code for acute and chronic pain 
impulses respectively. Panel b is a recording of a compound action potential from a nerve fiber. As 
shown, the Aα and Aβ fibers do not code for pain, but cause a large, rapid depolarization when activated. 
The first, acute pain impulse is carried by Aδ-fibers and is shorter in duration, while the second or chronic 
pain impulse is carried by the C fiber and is longer in duration. (From Julius and Basbaum, Nature 413, 
203-213, Sept. 2001) 
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1.2 CHRONIC PAIN 
1.2.1 The pathophysiology of chronic pain. 
 In the clinical setting, pain is chronologically graded as a spectrum of states ranging from 
acute pain that lasts from a few hours to 3 months, subacute pain lasting from 3 to 6 months and 
finally, chronic pain that lasts for greater than 6 months 7. Based on the eitiology, chronic pain is 
classified as inflammatory or neuropathic. Inflammatory pain in conditions such as arthritis and 
cancer occurs as a result of tissue damage, while neuropathic pain occurs as a result of neuronal 
damage and is associated with conditions like diabetes, spinal cord injury and stroke 8. Unlike 
acute pain, chronic pain often persists following a resolution of the underlying pathology and 
becomes associated with a separate set of psychosomatic symptoms that include immobility, 
depression, insomnia, reduced appetite and drug dependence to name a few (David Niv and 
Marshall Devor, Pain Practice, Vol. 4 Issue 3, 2004).  
 Concomitant with a distinct symptomatology, chronic pain causes changes in the 
expression profiles of several ion channels, receptors and cell signaling molecules at central and 
peripheral afferent terminals of nociceptive neurons 9. The resulting phenomena of peripheral 
and central sensitization occur due to complex morphological changes and phenotypic switches 
of neurons at different levels of the nociceptive pathway 10. Sensitization acts as a positive 
feedback loop for further development of the chronic pain state. This causes an enhancement of 
nociceptive function characterized by hyperalgesia in which less painful stimuli cause increased 
pain and allodynia defined as pain due to innocuous stimuli. Chronic pain can thus be regarded 
as a self-perpetuating disease entity characterized by distinct psychosomatic and molecular 
phenomena. Indeed, a recent declaration of the European federation of IASP chapters has called 
 7 
chronic pain “a disease in its own right” (David Niv and Marshall Devor, Pain Practice, Vol. 4 
Issue 3, 2004). 
1.2.2 Chronic pain from a public health perspective.  
 According to the Pain and Absenteeism in the Workplace Survey conducted by Louis 
Harris and associates in 1996, the United States currently has over 80 million full time 
employees that suffer from chronic pain. As a result of the reduced activity associated with 
chronic pain, there is an annual loss of 61.2 billion dollars in pain-related loss of productive 
time11 and 15 billion dollars are spent annually on pain medications. In addition to the economic 
costs, chronic pain significantly reduces the quality of life and is a major cause of depression 12. 
The treatment of chronic pain is therefore of prime importance from a public health as well as an 
economic perspective. 
1.2.3 Current treatments for chronic pain.  
 Chronic pain therapy includes a variety of approaches such as physiotherapy, 
acupuncture and pharmacological management. Several pharmacological agents summarized in 
table 1 are used to treat pain. Non-steroidal anti-inflammatory drugs (NSAIDs) act at the 
periphery of the nociceptive pathway while opiates such as morphine and anesthetics like 
lidocaine primarily exert their effects on receptors at the spinal level. Newer medications include 
anti-depressants such as amitryptyline that act at the supraspinal level.  
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Table 1. Analgesics in current use.  
Analgesics are classified based on level of action. Side effects for each drug class are given. 
        CLASS               NAME OF DRUG             LEVEL OF ACTION SIDE EFFECTS 
 
 
 
Non-steroidal  
anti-inflammatory  
drugs (NSAIDs) 
Acetaminophen, Methyl salicylate, 
Magnesium salicylate, Choline 
salicylate , Choline magnesium 
trisalicylate, Ibuprofen,  
Ketoprofen, Naproxen, Naproxen 
sodium, Carprofen, Diflunisal, 
Fenoprofen calcium, Etodolac, 
Ketorolac tromethamine, 
Mefenamic acid, Rofecoxib, 
Celecoxib. 
 
 
 
        
         Peripheral 
 
 
 
Nausea, vomiting 
diarrhea, gastric 
ulcers, colitis 
 
  Corticosteroids 
 
Dexamethasone, Prednisone 
      
         Peripheral 
Weight gain, 
gastic ulcers, 
cardiac problems 
    
     Anesthetics 
 
Mexiletine, Lidocaine, Ketamine 
    
   Peripheral and spinal 
Constipation, 
nausea, vomiting, 
arrythmias 
        
      Opioids 
Morphine, Codeine, Fentanyl, 
Hydrocodone, Hydromorphone, 
Levorphanol, Methadone, 
Oxycodone, Oxymorphone. 
 
            Spinal 
 
Dependence, 
tolerence 
   
  Antidepressants  
Amitriptyline, Desipramine, 
Maprotiline, Duloxetine, 
Nortiptyline, Venlafaxine. 
    
        Supraspinal 
Nausea, anxiety, 
weight gain, 
insomnia, 
constipation 
  Anticonvulsants 
Carbamazepine, Valproate, 
Gabapentin, Clonazepam, 
Lamotrigine, Pregabalin. 
     
        Supraspinal 
Excessive sleep, 
polyuria, 
polyphagia, ataxia 
 
 9 
1.2.4 Problems with current analgesics and strategies to improve analgesic efficacy. 
 Despite the availability of a large range of analgesics, chronic pain remains a difficult 
condition to treat. Most pain medications target molecules and receptors involved in biological 
systems other than nociception. The resultant side effects such as gastric ulcers associated with 
non-steroidal anti-inflammatory drugs (NSAID) and the drug dependence or tolerance associated 
with opiates 13 make the long-term use of current pain medications detrimental (see Table 1 for 
side effects of other medications). Indeed, according to the 1999 National Survey for chronic 
pain, 13.5 million people developed gastrointestinal problems and ulcers following the use of 
NSAIDs. It follows that the development of analgesics specifically targeting gene products 
upregulated in chronic pain may help reduce side effects, thus allowing a better management this 
malady.  
 One approach to achieve this goal is to recognize chronic pain as a distinct disease entity 
and identify the phenotypic cellular changes specific to chronic pain states. The vanilloid 
receptor (TRPV1, formerly known as VR1) has emerged as a classic example of an ion channel 
that is specifically upregulated in chronic pain. In addition to TRPV1, protein kinase C epsilon 
(PKCε) is thought to be an important pro-nociceptive kinase at the periphery of the nociceptive 
pathway. PKCε directly phosphorylates and enhances TRPV1 activity such that the receptor can 
be activated by lower doses of agonists 14, 15. TRPV1 hyperactivity is reflected as hyperalgesia 
and is a hallmark of the development of chronic pain states.  
 A second approach for the development of more effective analgesics with reduced side 
effects is the targeted delivery of chronic pain-specific inhibitory gene products to DRG neurons, 
which are effectively the primary sensors of painful stimuli. The herpes simplex virus 1 (HSV-1) 
is an attractive delivery vehicle for this purpose. HSV-1 is a large, neurotropic DNA virus that is 
 10 
retrogradely transported along DRG afferent neurons following a peripheral infection in the skin. 
Following retrograde transport through afferent nerve axons, HSV-1 loses the ability to replicate 
and attains a latent state in the neurons of the DRG for the lifetime of the host, but can retain the 
ability to express transgene products in these neurons when under the transcriptional control of 
immediate early promoters like the human cytomegalovirus (HCMV) promoter. This property 
makes HSV-1 a nearly ideal vector for the targeted expression of gene products to inhibit pain-
specific signaling molecules in nociceptive neurons. In this dissertation, the natural properties of 
HSV-1 as a vector delivery system have been exploited to develop tools and methods to identify 
chemical or natural inhibitors of TRPV1 (chapter 3) and to indirectly attenuate TRPV1 function 
by the inhibition of PKCε (chapter 4).  
The following sections will describe the role of TRPV1 and PKCε in nociception. In 
addition, the use of HSV-1 as a gene delivery vehicle to treat pain will be discussed in some 
detail. 
1.2.5 The vanilloid receptor and its role in nociception. 
 The vanilloid receptor or the transient receptor potential vanilloid 1 (TRPV1, formerly 
known as VR1) has recently emerged as an important receptor, the function of which is 
specifically upregulated in chronic pain states. TRPV1 is a peripheral pro-nociceptive Ca+2 ion 
channel belonging to the transient receptor potential (TRP) superfamily 16. TRP ion channels are 
cellular physiological sensors involved in a variety of important biological functions ranging 
from hearing to brain development 17, 18. A growing subfamily of TRP ion channels directly 
activated by a variety of specific chemical agonists and temperatures ranging from noxious cold 
to noxious heat have recently been uncovered (Fig. 3) 19, 20. Of these, TRPV1 is the direct 
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peripheral sensor of noxious stimuli that include heat (43°C) 21, endovanilloids (anandamide) 22, 
23, low pH (protons), capsaicin and resiniferatoxin 24-26. A network of G-protein coupled 
receptors including those responsive to bradykinin (BK), nerve growth factor (NGF) and ATP 
cause the phosphorylation and consequent potentiation of TRPV1 function such that sub-
maximal doses of direct stimuli become capable of activating the receptor 27-30. The TRPV1 
hyperactivity that occurs through this complex array of mechanisms results in the development 
of voltage gated sodium channel (VGSC)-induced neuronal hyperexcitability seen in chronic 
pain 31. Being an important pro-nociceptive molecule, TRPV1 is subject to stringent regulatory 
mechanisms like calcineurin mediated receptor dephosphorylation 32 and tonic TRPV1 inhibition 
by phosphoinositol diphosphate (PIP2) 33. Additionally, neurotrophin three (NT-3) causes long-
term down-regulation of TRPV1 34. TRPV1 knockout mice exhibit reduced responses to noxious 
thermal stimuli and acidic pH in the setting of inflammation 35, which underscores the 
contribution of TRPV1 to the pain signaling pathway. These vital roles of TRPV1 in peripheral 
pain signaling suggest that a further understanding of the regulatory circuits that control TRPV1 
function may provide insights into novel means of controlling receptor expression or function 
and may thereby provide new targets for the treatment of chronic pain. 
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Figure 3. The transient receptor potential family of ion channels.  
 The figure depicts recently discovered members of the transient receptor potential (TRP) 
family of ion channels involved in sensing a variety of temperatures. The canonical TRP (TRPC) is a 
classical TRP ion channel, while the vanilloid subfamily (TRPV) can be broken down into four members 
TRPV1 to 4 that detect the temperatures shown for each channel. The melastatin (TRPM8) and the 
Ankyrin (ANKTM1 / TRPA1) TRPs detect cold temperatures below 25˚C and 17˚C respectively. 
1.2.6 The role of protein kinase C epsilon (PKCε) in nociception. 
 The evolutionarily conserved protein kinase C (PKC) family of enzymes are 
involved in a myriad of functions ranging from development to pain perception. These kinases 
are divided into three subtypes based on their co-factor requirements. The conventional isoforms 
(cPKCs – PKCα, PKCβ and PKCγ) depend on diacylglycerol (DAG) and Ca+2 for their 
activation, while the novel isoforms (nPKCs - PKCδ, PKCε, PKCη and PKCθ) are activated by 
DAG in a Ca+2 independent manner. Atypical isoforms (aPKCs - PKCζ and PKCλ) are a third 
subtype, activated independent of DAG and/or Ca+2 36.  
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Among these kinases, the novel protein kinase PKCε plays a crucial role in oncogenesis, 
ethanol sensitivity, neurite outgrowth, cardiac reperfusion following ischemia and cytoskeletal 
re-organization 37. In addition to these functions, PKCε is a pro-nociceptive signaling molecule 
in nociceptive neurons 38. Thus, the functions of this kinase vary depending upon the type of 
tissue or cell in which it is expressed. Recent studies in PKCε and TRPV1 knockout mice 
demonstrate reduced painful behaviours in response to thermal stimuli and the PKC activator, 
phorbol myristate acetate (PMA) respectively 38, 39. These results indicate that PKCε may exert 
its pro-nociceptive function by exclusively acting through the TRPV1 receptor. Indeed, 
PKCε has recently been shown to directly phosphorylate TRPV1 at the Ser502 and Ser800 
residues in-vitro and in-vivo 15, 30. TRPV1 phosphorylation results in enhanced receptor function 
such that the receptor is now activated by lower doses of chemical agonists and physiological pH 
and temperature (37˚C). This phenomenon, called receptor sensitization is critical to the 
development of chronic pain states 40. In nociceptors, PKCε is activated downstream of several 
G-protein coupled receptors including the bradykinin receptor 2 and the purigenic P2Y2 receptor 
resulting in TRPV1 sensitization 27, 41. Since inflammatory mediators such as bradykinin and 
ATP directly activate these receptors, PKCε activation in nociceptors is physiologically relevant 
in the context of inflammation and the development of a chronic pain state. 
Given the importance of PKCε in nociception and chronic pain, the targeted inhibition of 
this kinase in nociceptive neurons, described in chapter 4, may represent a novel strategy to 
reduce TRPV1 function and thereby curb the development of a chronic pain state.  
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1.2.7 Replication defective herpes simplex virus-1 (HSV-1) vectors. 
 A prerequisite for the safe use of HSV-1 as a gene delivery vector is to attenuate 
pathogenic attributes of the virus. Viral mutants have been engineered that are non-cytopathic 
and do not disturb host cell gene expression, yet remain capable of transgene expression in the 
sensory neurons of animals 42. During its replicative cycle, HSV-1 undergoes a highly regulated 
and inter-dependent temporal cascade of viral protein expression (Fig. 4) 43. The immediate early 
proteins, infected cell protein (ICP) 0, ICP4, ICP22, ICP27 and ICP47 are expressed within an 
hour following viral attachment and entry into epithelial cells of the mucosa. These proteins in 
turn cause the expression of early viral proteins that are involved in viral DNA replication. Early 
viral proteins trigger the expression of late viral genes that code for structural components of the 
virus.  
 The deletion of immediate early viral genes in a variety of combinations results in 
replication defective HSV-1 viruses that are incapable of reactivation or replication in non-
complementing cells. These mutant vectors are consequently suited for the in-vivo delivery of 
therapeutic transgenes. Virus replication and propagation can only be achieved by the in-vitro, 
in-trans complementation of viral functions using cell lines that express the deleted viral proteins 
44, 45. 
 
 15 
 
 
Figure 4. HSV-1 virus replication cascade. 
 The figure depicts the normal, temporally regulated HSV-1 replication cascade. Following viral 
entry into the cell, the virion component VP16 activates viral promoter sequences of the immediate early 
genes. This in turn causes the activation of early genes that are involved in viral DNA replication. Early 
gene products trigger the expression of late genes that code for virion components. Of the immediate 
early gene products, ICP4 and ICP27 are essential for replication in-vitro. Viruses that are deleted for 
these gene products are therefore replication defective in-vivo and in non-complementing cell lines. 
(Adapted from Burton et al, Stem Cells, 2001 19(5): 358-77) 
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1.2.8 Herpes Simplex 1 Virus (HSV-1) and the treatment of pain. 
HSV-1 has many biological features that make it attractive for gene delivery to the 
nervous system 46-48. As mentioned earlier, in natural infection, the virus establishes latency in 
DRG neurons, a state in which viral genomes may persist for the life of the host as intranuclear 
episomal elements. Several reports reveal the potential efficacy of HSV-1 to treat neuropathic, 
inflammatory and bone cancer pain. Salient findings from these reports are described below.  
Replication-competent HSV-based vectors expressing proenkephalin (PE) display an 
anti-hyperalgesic effect following subcutaneous footpad injection in mice. This was 
demonstrated by an increased latency to foot withdrawal from noxious heat after sensitization of 
C-fibers by application of capsaicin, or sensitization of Aδ-fibers by application of dimethyl 
sulfoxide 49. Another replication-competent HSV-based vector expressing proenkephalin reduced 
pain in a rodent model of arthritis 50. Effects of replication-defective vectors expressing PE from 
the HCMV IE promoter (SHPE) in the formalin model of inflammatory pain have also been 
examined. Rats injected with SHPE one week prior to formalin testing showed a significant 
reduction in nocisponsive behaviors 51. The behavioral response of SHPE-inoculated animals to 
inflammatory pain waned over a period of weeks as did PE expression from the vector. 
However, vector re-inoculation re-established the anti-nociceptive effect, suggesting that the loss 
of effect was not a result of tolerance to vector-mediated opioid expression. This demonstrated 
that prior inoculation with a non-replicating vector does not prevent the re-application of 
therapeutic gene transfer with the HSV-1 vector. Similar anti-nociceptive effects have been 
observed in the spinal nerve ligation (SNL) model of neuropathic pain, where vector re-
inoculation could re-establish the analgesic effect 52. Potential therapeutic effects of HSV-
mediated PE expression have also been evaluated in a mouse osteosarcoma model of pain due to 
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metastatic bone cancer. Animals injected with SHPE demonstrated a significant reduction in 
spontaneous pain behavior 2 and 3 weeks after tumor implantation 53.  
Recent publications show that the expression of glial-derived neurotrophic factor 
(GDNF) effectively suppresses allodynia caused by the neuropathic spinal nerve ligation model 
54. A replication defective vector expressing GAD67 (glutamic acid decarboxylase) that results in 
the conversion of glutamic acid to GABA (gamma-amino butyric acid), a potent inhibitory 
neurotransmitter produced GABA and in a model of below level spinal cord injury (SCI), 
effectively reversing mechanical allodynia and thermal hyperalgesia. These results suggest that 
HSV-mediated gene transfer to DRG could be used to treat below-level central neuropathic pain 
after incomplete SCI. This GAD67 expressing vector is effective at treatment of neuropathic pain 
in animals models when delivered by peripheral inoculation 55. 
Taken together, these results clearly demonstrate the usefulness of replication defective 
HSV-1 vectors as a gene delivery vehicle to treat chronic pain. In addition to the use of HSV-1 
as a gene therapy vector, properties like neurotropism, the ability to simultaneously express 
multiple transgenes and a large transgene capacity make replication defective HSV-1 vectors an 
attractive expression system for the in-vitro applications described in this dissertation. 
1.3 SPECIFIC AIMS 
 The first part of my thesis focuses on the design and development of a selection system 
using replication defective HSV-1 vectors as a tool to identify novel inhibitors of ion channels 
involved in nociception. Given the established role of TRPV1 in nociception, this receptor has 
been used as a target gene to develop the selection system.  
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 In the second part of my thesis, I have tested the hypothesis that the HSV-1 vector-
mediated targeted functional inhibition of a known pro-nociceptive molecule, PKCε in DRG 
neurons at the periphery of the nociceptive pathway is a means to attenuate TRPV1 activity in-
vitro and in-vivo. The following sections describe these specific aims in some detail. 
1.3.1 Specific aim 1.  
 Several ion channels such as purigenic receptors, voltage gated calcium channels and 
specific subtypes of sodium channels are upregulated in chronic pain states 5, 56. Specific aim 1 
focuses on the development and characterization of an HSV-1 vector-based selection system to 
identify inhibitors of these nociceptive ion channels. The TRPV1 receptor is a prototypical 
example of an ion channel that is upregulated in chronic pain states. Using TRPV1 as a model 
receptor and exploiting the natural properties of replication defective HSV-1 vectors as a gene 
expression tool, a selection system is developed that can be used to identify novel inhibitory 
cDNA products or chemical antagonists of TRPV1. The system is based on the idea that 
activation of HSV-1 vector-expressed TRPV1 by TRPV1-specific agonists will result in an 
influx of cytotoxic levels Ca+2 into the cell. This will cause cell death before the virus can 
complete its replicative cycle. A fall in viral titers is thus an indirect indicator of TRPV1 receptor 
activation by agonists. Selection is based on the rationale that antagonism of receptor activation 
will prevent cell death and allow the viral replicative cycle to reach completion. Thus the 
recovery of viral growth is an indirect indicator of receptor antagonism by chemical or natural 
antagonists. The design, development and characterization of this HSV-1 vector-based selection 
system will be described in chapter three. As a platform system, selection can be adapted to 
identify natural or chemical inhibitors of several other ion channels known to be upregulated in 
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chronic pain. The identification of novel and specific inhibitors of these ion channels has direct 
implications for the development of better and more specific analgesics with reduced side effects 
to treat chronic pain.  
1.3.2 Specific aim 2.     
 Specific aim 2 focuses on the use of HSV-1 vector-expressed dominant negative protein 
kinase C epsilon (PKCε) as an approach to attenuate TRPV1 receptor function in-vitro and in-
vivo.  PKCε  is a pro-nociceptive protein kinase that is activated by G-protein coupled 
mechanisms downstream of the purigenic receptor, P2Y2 and bradykinin receptor 2. Following 
activation, PKCε directly phosphorylates and potentiates TRPV1 function such that the receptor 
is maximally activated by lower doses of natural and chemical agonists 14, 15, 57, 58. A study in 
TRPV1 knockout mice has demonstrated the absence of nocifensive behaviors following 
stimulation with the known PKC activator, phorbol myristate acetate (PMA) in knockout mice, 
while wild-type mice display painful behaviors in response to PMA 39. This result shows that 
PKCε acts exclusively through the TRPV1 receptor to cause pain. Thus, PKCε coupled to 
TRPV1 hyperactivation may be specifically involved in the transition from acute to chronic pain 
states. The targeted inhibition of PKCε function in nociceptors can therefore be a strategy to 
specifically attenuate TRPV1 function in nociceptors and thereby prevent the development of a 
chronic pain state. Although PKCε plays a pro-nociceptive role in DRG neurons, other functions 
of this molecule include neurite outgrowth, anti-apoptosis and cardiac reperfusion following 
ischemic injury to cardiomyocytes 37. In this aim, the neurotropism of HSV-1 has been exploited 
to achieve the targeted inhibition of endogenous PKCε activity, thereby attenuating TRPV1 
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function in nociceptors without interfering with other biological systems. Chapter four describes 
experiments to evaluate the inhibition of PKCε by HSV-1 vector-mediated dominant negative 
PKCε transgene expression as a means to attenuate TRPV1 function in-vitro and in-vivo. 
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2.0 MATERIALS AND METHODS 
2.1 HSV-1 VECTOR CONSTRUCTS AND PLASMIDS 
 The HSV-1 vectors used in this dissertation were derived from the wildtype HSV-1 KOS 
strain 17. The vectors utilized were QOZ (Quadruple mutant backbone, ICPOp:LacZ), vHDNP 
(vector HCMVp:Dominant Negative PKCε), vHG (vector HCMVp:EGFP) and vTT (vector 
TKp:TRPV1). These vectors are replication defective mutants, deleted for the immediate early 
essential genes, ICP4 and ICP27. Deletion of immediate early genes impairs the ability of these 
mutant vectors to replicate in non-complementing cells, making in-trans complementation of the 
ICP4 and ICP27 gene products a requirement in order to replicate in-vitro. This is achieved by 
propagating the vectors in a 7B cell line complementing for deleted viral functions 44, 45. To 
construct the recombinant viral vectors, plasmids were recombined into the targeted locus of 
parent vectors by sequential virus infection and plasmid transfection. Screening for marker gene 
transfer (e.g. EGFP negative plaques) was used to isolate recombinants 59. Vector plaques were 
purified by three rounds of limiting dilution and verified by Southern blot analysis. Confirmed 
vector stocks were expanded in complementing cells, purified by centrifugation to remove 
excess proteins, titered on complementing cells, aliquoted and stored at –80˚C. The vectors were 
chronologically engineered as follows: 
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2.1.1 Construction of the QOZ and vHDNP vectors. 
 The QOZHG vector (ICP4-,ICP27-, ßICP22,ßICP47, ICP0p:LacZ::UL41, 
HCMVp:EGFP::ICP27) 60 which is derived from a cross of mutants TOZ.1 44, 45 and d106 virus 
61 was deleted for the EGFP expression cassette by homologous recombination with plasmid 
pPXE. pPXE contains a BamHI-SalI deletion of the UL54 (ICP27) coding sequence with a PmeI 
linker inserted between the BamHI and SalI sites 62. The resultant vector, QOZ (ICP4-,ICP27-
,ßICP22,ßICP47, ICP0p:LacZ::UL41), was then similarly recombined to contain a dominant 
negative PKCε cassette fused to GFP and driven by the HCMV promoter (HCMVp:DNP) at the 
UL41 locus using the plasmid p41HDNP. The vector resulting from this recombination was 
called vHDNP. Plasmid p41HDNP contains the HCMVp:DNP cassette flanked by UL41 
homology sequences and was constructed as follows:  
The dominant negative PKCε construct, HDNP was engineered based on previously 
published work 63 and is deleted for the entire catalytic region, the C2 and the C1b sub-domains. 
The construct retains the pseudosubstrate region (PS), the C1a sub-domain and a variable region 
(V3) of the PKCε regulatory domain. This construct is fused to the enhanced green fluorescent 
protein (EGFP). In order to engineer, HDNP the PKCε cDNA was isolated by RT-PCR from the 
total mRNA of SH-SY5Y human neuroblastoma cells, obtained using the RNeasy minikit 
(Qiagen, Valencia, CA). The PKCε cDNA regulatory domain was then cloned into the SalI to 
BglII sites of the pEGFPN1 vector (Clontech laboratories, Inc.) by standard restriction digestion, 
ligation and sub-cloning techniques. The resultant plasmid contains the HCMV promoter in front 
of the PKCε regulatory domain fused to EGFP. The above plasmid was PCR amplified using 
primers that each contained an MluI site (upper primer is 5’-
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GCGACGCGTGCCAAAGTACTGGCCGACCTG-3’ and lower primer is 5’-
GCGACGCGTGATACCGAACTTGTGGGGCAT-3’) such that parts of the cDNA coding for 
C2 and C1b regulatory sub-domains were deleted following cleavage of the PCR product with 
MluI and re-ligation to create a dominant negative PKCε construct fused to GFP and driven by 
the HCMV promoter (HDNP). The HDNP construct was isolated as a BamH1 fragment and 
cloned into the BamH1 site of plasmid p41 to create p41HDNP that contains the dominant 
negative PKCε construct (HDNP) with homologous flanking sequences for the UL41 locus of 
HSV-1. The vector, vHDNP was created by replacing the ICPO:LacZ cassette at the UL41 locus 
of QOZ with HDNP. This was achieved by homologous recombination between p41HDNP and 
the UL41 locus of the QOZ vector. Recombinants were isolated using GFP as a marker. The 
UL41DNP locus was PCR amplified from the vHDNP viral DNA and sequenced prior to 
performing experiments. 
2.1.2 Construction of the vHG vector. 
 QOZ was deleted for the ICP0p:LacZ expression cassette present in the UL41 locus using 
plasmid p41 to make virus Q (ICP4-,ICP27-,ß22,ß47). An HCMV immediate early (IE) promoter 
driving EGFP (HCMVp:EGFP) was engineered into the ICP4 loci between the AflIII-StyI (HSV 
bases 126413 to 131879) of the Q vector, to make vHG (ICP4-,ICP27-,ßICP22,ßICP47 
HCMV:EGFP::ICP4) that has an expanded ICP4 deletion and truncated ICP22 and ICP47 
promoters compared to parental vectors. 
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2.1.3 Construction of the vTT vector. 
  The vTT vector (ICP4-, ICP27-, ßICP22, ßICP47, TKp:TRPV1::ICP4) was constructed 
by replacing the HCMVp:EGFP cassette in the ICP4 locus of vHG with a TRPV1 cDNA driven 
by the early HSV-1 TK promoter (TKp:TRPV1) using plasmid pTT. pTT was constructed by 
inserting the PvuII-BglII fragment of pUX containing the early TK promoter and the Asp718-
NotI fragment containing the rat TRPV1 coding sequence (Kind gift of D Julius) 21 into plasmid 
pSASB3. Plasmid pSASB3 contains the SphI-AflIII and StyI-EcoRII fragments flanking the ICP4 
coding sequence with a unique BamHI linker present between the two fragments. 
2.2 CELLS, CELL CULTURE, VIRAL INFECTIONS AND TRANSDUCTION 
2.2.1 Complementing and non-complementing Vero and U2OS cell lines. 
 Several experiments in chapter three make use of a complementing cell line (7B cell line) 
that expresses the ICP4 and ICP27 viral proteins in-trans 44, 45. This allows the in-vitro 
propagation of ICP4-, ICP27- replication defective HSV-1 vectors. The non-complementing Vero 
and U2OS cell lines were used for immunostaining and Western blot experiments in chapters 3 
and 4 respectively. 7B, Vero and U2OS cell lines were grown and maintained in Dulbecco’s 
Minimum Essential Medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM L-
glutamine and 100 U/ml penicillin/streptomycin (all media components from Life Technologies 
Inc.). Cells were subcultured in 150 cm2 vented cap polystyrene tissue culture flasks 
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(Falcon/Becton Dickinson, San Diego, CA) and incubated at 37°C in a humidified 5% CO2 
incubator. 
2.2.2 Primary neuronal cell culture. 
 The adult rat DRG neurons used for experiments in chapter four were isolated by 
standard enzymatic techniques as previously described for isolation and culture of rat DRG 
neurons 64. Briefly, freshly dissected ganglia were minced and washed in cold, oxygenated 
DMEM (Sigma). This was followed by 10 min dissociation at 37˚C in DMEM containing 0.5 
mg/ml trypsin (Sigma). After a 10 min centrifugation, the media was replaced with DMEM 
containing 1 mg/ml Collagenase B (Boehringer-Mannheim) and 0.5 mg/ml Trypsin Inhibitor 
type 1S (Sigma). Dissociation of neurons was continuously monitored and the cells were gently 
triturated with siliconized Pasteur pipettes every 10 min. After the ganglia dissociated into 
individual neurons (25-40 min.), the cell suspension was centrifuged for 10 min at 1200 rpm. 
The pellet was layered on 20 ml of 50% adult bovine serum (Sigma) and DMEM and centrifuged 
again at 800 rpm. This step removes most debris and broken cells. The pellet was then 
resuspended in DMEM containing 10% heat inactivated horse serum and 5% fetal bovine serum 
(Sigma), and plated on collagen coated 35 mm petri-dishes (Collaborative Research, Biocoat) or 
35 mm Petri dishes with 10 mm glass bottom microwells (Mattek Corporation, Ashland, MA) for 
imaging experiments. Neurons were plated at low density (2000-3000 per dish) and the primary 
cultures were incubated in a 95% air, 5% CO2 humidified incubator at 37oC for three to four days 
prior to infection with HSV-1 vectors. 
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2.2.3 Infection and transduction: A note on the terminology. 
 In this thesis, the term infection has been used to denote the process of attachment and 
entry of HSV-1 vectors with consequent virus replication in complementing 7B cell lines, while 
the term transduction has been used to denote HSV-1 vector attachment and entry and the 
consequent expression of transgenes in neurons, non-complementing Vero and U2OS cells. 
Thus, the difference between infection and transduction lies respectively in the presence or 
absence of replication after HSV-1 vector entry into the cell. 
2.2.4 Methods for infection and cell transduction with HSV-1 vectors and general 
methodology for TRPV1 functional assays.  
 HSV-1 infections for complementing 7B cells were done in suspension in 15 ml conical 
tubes (Falcon) with DMEM media containing 10% FBS, and rocked on a nutator platform 
(Becton Dickinson) for 1 hour at 37°C. The vector-transduction of non-complementing Vero and 
U2OS cells was performed in a similar manner.  
 For TRPV1 functional studies, 250,000 cells per well were plated in 24 well plates 
containing required final concentrations of reagents in 1 ml of DMEM with 10% FBS, and 
incubated at 37°C in a humidified 5% CO2 incubator. Supernatant samples collected at 24, 48 
and 72 hrs post-infection (hpi) were titered by a standard viral plaque assay 59. The number of 
plaques for each viral dilution was counted and titers were expressed as viral plaque forming 
units (PFU) per ml of viral suspension.  
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2.2.5 Transduction of primary neuronal cultures with HSV-1 vectors. 
 Primary neuronal cell cultures were incubated at 37˚C for three to four days prior to 
transduction with HSV-1 vectors. This allowed the growth of supporting fibrablasts and 
prevented sloughing of the neurons during and after transduction. Transduction was performed 
one day prior to the experiments. 107 PFU of vHG or vHDNP vectors were suspended in 600 µl 
of DMEM media containing 5% FBS and 10% heat inactivated HS. Media in the 35 mm Petri 
dishes was replaced with 600 µl of the above media containing 107 PFU of viral vectors. The 
viral inoculum (600 µl) was allowed to incubate overnight at 37˚C on the neuronal monolayer 
and experiments were performed the following day as required. Figure 5 is a schematic depicting 
the general methodology followed for the transduction of primary DRG neurons. As shown in 
the panels at the bottom of the figure, nearly 100% transduction efficiency of neurons and 
supporting cells in culture was achieved by following this method. 
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Figure 5. Method for transducing DRG neurons with HSV-1 vectors. 
 The figure is a schematic showing the methodology followed for transducing DRG 
neuronal cultures with HSV-1 vectors. The panels at the bottom of the figure show that nearly 100% of 
neurons were transduced by this method using the HSV-1 vector, vHG. 
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2.3 SOUTHERN BLOTTING 
 Viral DNA extracted by spooling from 3 million 7B cells infected at a multiplicity of 
infection (MOI = number of plaque forming units or PFU per cell) of 3 was used for Southern 
blotting 62. Southern blotting was performed using a North2South kit (Pierce, Rockford, IL) as 
per the manufacturer’s instructions. Briefly, ~1ug viral DNA extracted as above was digested 
with restriction enzymes and bands were electrophoretically separated. Following overnight 
transfer to a nitrocellulose membrane, hybridization with biotinylated probe was carried out 
overnight at 55˚C. The blot was then washed and developed with luminol. Signals were detected 
by autoradiography and scanned. A 10Kb biotinylated lambda plus marker (New England 
Biolabs, Catalogue # N75545) was used as the molecular weight marker for all southern blots. 
2.4 WESTERN BLOTTING 
 Western blotting was performed to confirm the expression of GFP by vHG and DNP 
fused to GFP by vHDNP in vector-infected 7B, or vector-transduced Vero and U2OS cells. The 
cells were infected / transduced with the viral vectors, harvested with 1X NuPAGE LDS Sample 
Buffer in PBS (Invitrogen, Carlsbad, CA) and heated at 70
o
C for 10 minutes. Each protein 
sample was loaded into duplicate wells on NuPAGE Novex Tris-Acetate gel (Invitrogen, 
Carlsbad, CA) and electrophoresed. The gel proteins were then transferred onto Immobilon-P 
PVDF membrane (Millipore, Billerica, MA). The membrane was cut into strips representing 
duplicate wells for a particular vector infection and cell line. The membranes were probed 
overnight at 4
o
C with a 1:500 dilution of goat polyclonal antibody against GFP (Abcam, 
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Cambridge MA) in PBS containing 2% dry milk. The membranes were then washed with PBS 
containing 0.05% tween-20, incubated with a 1:7000 dilution of donkey anti-goat horseradish 
peroxidase conjugated antibody (Sigma, St. Louis, MO) in 2% milk for 1 h at 25
o
C. After 
additional washes, the membranes were juxtaposed and the signals were developed on one X-ray 
film according to the standard protocol using the Amersham ECL kit (Amersham Pharmacia 
Biotech, Piscataway, NJ). 
2.5 IMMUNOCYTOCHEMISTRY 
For immunocytochemical analysis in Vero and complementing 7B cells, cells were infected with 
either vHG or vTT (18 hpi, 0.3 PFU/cell) and plated in an eight microwell glass bottom slide 
(Falcon). Following fixation in 4% formaldehyde at RT for 10 minutes, infected cells were 
washed twice with PBS, and then permeabilized in 0.001% Triton-X 100 for 10 minutes at RT. 
Slides were blocked with 10% horse serum (HS) in PBS for one hour at RT then incubated for 
one hour with either the TRPV1 (1:300, EMD Biosciences Oncogene Research Products, LA 
Jolla, CA) or an ICP0 (1:500, raised in rabbits against the 30 C-terminal residues of the ICP0 
protein) antibody. Slides were washed in PBS and incubated at RT for one hour with a TRITC 
labeled goat anti-rabbit IgG secondary antibody (1:500, Sigma, St Louis, MO). After washing 
with PBS, coverslips were applied and images captured using a Zeiss inverted fluorescent 
microscope with Axiovision software (Carl Zeiss Microimaging Inc., Thornwood, NY). 
 For immunocytochemistry in adult rat DRG neurons were plated in a 35 mm petri 
dish with 10 mm glass bottom at a density of 200 cells per dish. Four days after culture, neurons 
were transduced in a monolayer with either vHG or vHDNP (107 PFU per petri dish). The 
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following day (16 hpi.), vector-transduced dishes were incubated with 5 µM phorbol dibutyrate 
(PDBu) for 2 min as required and then immediately fixed for 20 minutes at RT in 2% 
paraformaldehyde. Following two washes in PBS, cells were blocked with 10% HS in PBS for 
one hour and then incubated for one hour in 1% HS in a rabbit PKCε anitbody (1:300 dilution). 
The PKCε antibody used for this purpose is developed in rabbit using a synthetic peptide (Lys-
Gly-Phe-Ser-Tyr-Phe-Gly-Glu-Asp-Leu-Met-Pro) corresponding to the C-terminal variable (V5) 
region (amino acids 726-737) of PKCε (Sigma St. Louis Missouri). Dishes were then washed 
with PBS and incubated for one hour with a Cy3 labeled goat anti-rabbit secondary antibody 
(1:300 dilution, Sigma). It should be noted that no permebealization was performed for PKCε 
immunostaining in order to prevent artifacts due to the disruption of protein subcellular 
localization that can occur following permebealization. Images were captured in multiple planes 
(4 to 6 planes) for each neuron with a Zeiss 510 meta inverted fluorescent microscope using 
green and red channels. Images are presented as stacked projections of multiple planes for each 
transduced neuron and were processed using the ImagePro image processing software. 
2.6 LIVE CELL IMAGING 
 Vero and U2OS cells were transduced in suspension with the vHDNP vector (MOI 3) for 
1 hour at 37˚C. Cells were plated in 10 mm glass bottom microwells of 35 mm Mattek petri 
dishes at a density of 40,000 cells per dish. For live cell imaging in neurons, cells were 
transduced in monolayer 4 days after plating freshly dissociated DRG neurons at a density of 500 
cells per Mattek petri dish. Cells were visualized using a Leica TCS NT inverted fluorescent 
microscope. Phorbol myristate acetate (PMA) was added directly to the media in the Mattek petri 
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dishes to achieve a final concentration of 5µM PMA. Immediately after PMA stimulation, cell 
images were recorded at 2-second intervals, for the duration of the experiment, which lasted 
from 2 to 3-min. Translocation of the green fluorescent transgene product (DNP fused to GFP) 
was captured using a green fluorescent filter. The movies were recorded in Dr. Simon Watkins 
laboratory (Center for Biological Imaging, University of Pittsburgh, Pittsburgh PA).  
2.7 WHOLE CELL PATCH CLAMP RECORDINGS 
Gigaohm-seal whole-cell recordings of capsaicin induced currents were recorded in Vero 
cells and adult DRG neurons transduced with vTT, vHG or vHDNP vectors (20 hpi, 10 PFU/cell 
for Vero cell recordings and 16 hpi, 107 per petri dish for rat DRG neurons) or non-transduced 
cells using whole cell patch clamp techniques. Patch pipettes were pulled from capillary glass 
tubes (Accufil 90, Clay-Adams) and fire polished. Immediately before recording, the serum 
containing media was replaced with phosphate buffered saline. Whole cell currents were voltage 
clamped using an Axopatch 200A (Axon Instruments, Foster City, CA) amplifier. Pulse 
generation, current recording and data analysis used pClamp software (Axon Instruments). 
Currents were sampled at 500 μs, and filtered at 2 kHz. Capacitive currents and up to 80% of the 
series resistance were compensated. A p/4 protocol was used to subtract uncompensated 
capacitative currents and leak currents. The decay of TRPV1 currents in response to capsaicin 
and after addition of the phorbol ester, phorbol 12,13-dibutyrate (PDBu) or the PKC inhibitor 
bisindolylmaleimide I HCl (BIM) in the presence of capsaicin was fitted with single exponentials 
using pClamp software regression analysis. To determine the kinetics and voltage dependence of 
activation and inactivation of outward currents, a combined two pulse activation-inactivation 
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protocol was used, consisting of series of rectangular pre-pulses from a holding potential of -90 
mV. The pre-pulse, 1000 ms in duration, ranging from –140 to +90 mV was used to generate 
current activation. The inactivation curve was measured after a brief, 23 ms interpulse at -80 mV 
and a second test pulse to +60 mV, 250 ms in duration. Peak current amplitudes were measured 
with pClamp software. 
 The extracellular solution was Dulbecco phosphate buffer (Sigma, St. Louis, MO). The 
pipette (intracellular) solution contained (mM): KCl 120, K2HPO4 10, NaCl 10, MgCl2 2, EGTA 
1, HEPES 10, pH adjusted to 7.4 with HCl. To this solution Mg-ATP (3 mM), cAMP (0.3 mM) 
and tris-GTP (0.5 mM) were added just prior to the experiments. Capsaicin (Calbiochem, San 
Diego, CA), a TRPV1 antagonist (Neurogen, Branford, CT), the phorbol ester, phorbol 12,13-
dibutyrate (Research Biochemicals, Natcik, MA), and the PKC inhibitor bisindolylmaleimide I 
HCl (Calbiochem, San Diego, CA) were dissolved in DMSO (100 mM) and used at less than 
0.01% of their stock concentration. At these dilutions, DMSO alone had no effect on TRPV1 
responses to capsaicin. Ruthenium Red (RuR) was prepared in aqueous solutions. Stock 
solutions in 10-100 mM were stored at -20o C and diluted in the external recording solution just 
before use. The TRPV1 antagonist (diaryl piperazine, NDT9515223) was a gift from Neurogen 
(Branford, CT) and was shown previously to be a potent and selective TRPV1 inhibitor (Ki = 7 
nM) 65. Extracellularly applied drugs were pipetted from stock solutions at 10 to 100 times the 
final concentration and rapidly mixed in the recording chamber as described previously 64. 
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2.8 INTRACELLULAR CALCIUM MEASUREMENT 
 Free intracellular calcium was measured by photon scanning on a dual excitation 
fluorimeter (PTI, Lawrenceville, NJ). vTT or QOZ infected 7B cells were plated in 6 well plates 
containing 13.5 x 20 mm coverslips. Infected cells (8 hpi, 3 PFU/cell) were rinsed with 1X 
Hank’s balanced salt solution (HBSS) and loaded with 2 µM FURA-2 (Molecular Probes Inc., 
Eugene, OR) 66 for 1 hour at 37˚C in a 5% CO2 incubator. Coverslips with FURA-2 loaded cells 
were then placed in a cuvette containing HBBS and then separately subjected to capsaicin at 
either 3 or 0.3 µM concentrations. Calcium flux following the application of each concentration 
of capsaicin was measured at 2 Hz and graphed. Results were calibrated by adding 5 µM 
ionomycin to obtain the maximum fluorescence ratio, followed by addition of 10 mM EGTA to 
obtain the minimum fluorescence ratio. A Kd of FURA-2 for calcium of 224 nM was assumed. 
2.9 DETECTION OF MITOCHONDRIAL PERMEABILITY TRANSITION AND 
CASPASE ACTIVATION 
 The DePsipher kit (R&D systems, Minneapolis, MN) was used to detect the initiation of 
mitochondrial permeability transition (MPT) in 7B cells. Briefly, vTT or QOZ infected cells (12 
hpi, 0.1 PFU/cell) were incubated with 3 µm capsaicin for one hour at 37˚C in a 5 % CO2 
incubator. Cells were then loaded with 1 µl DePsipher/ml in pre-warmed culture media for 15-20 
min at 37˚C in a 5% CO2 incubator. Following two washes in prewarmed media, cells were 
immediately imaged using an inverted fluorescence microscope (Carl Zeiss Inc.).  
 For activated caspase detection, the CaspACE FITC-VAD-FMK In- Situ Marker kit 
(Promega, Madison, WI) was used.  Briefly, CaspACE FITC-VAD-FMK was added to a final 
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concentration of 10 µM to 7B cells infected with vTT or QOZ virus (12 hpi, 0.3 PFU/cell). Cells 
were incubated for 20 minutes at 37˚C in a 5 % CO2 incubator. Following two washes in PBS, 
cells were fixed for 30 minutes in 4 % formalin, washed three times with PBS and imaged using 
an inverted fluorescence microscope (Carl Zeiss Inc.). 
2.10 VIRAL GROWTH ASSAYS 
 Infections for all TRPV1 functional studies were done in suspension in 15 ml conical 
tubes (Falcon) with DMEM media containing 10 % FBS, and rocked on a nutator platform 
(Becton Dickinson, San Diego, CA) for 1 hour at 37°C. Cells were pelleted by centrifugation at 
1000 rpm for 5 min and resuspended in 1ml of fresh DMEM. 250,000 cells per well were plated 
in 24 well plates containing required final concentrations of reagents in 1 ml of DMEM with 10 
% FBS, and incubated at 37°C in a humidified 5% CO2 incubator. Supernatant samples collected 
at 24, 48 and 72 hrs post-infection (hpi) were titered by a standard viral plaque assay 59. The 
number of plaques for each viral dilution was counted and titers were expressed as viral plaque 
forming units (PFU) per ml of viral suspension.  
2.11 COBALT UPTAKE ASSAYS 
 Cobalt uptake assays were performed to identify TRPV1 activity in adult rat DRG 
neurons. The assay was performed according to a previously described method 67. Briefly, non-
transduced and vHG or vHDNP-transduced neurons in culture were washed twice in buffer A 
(NaCl, 57.5 mM; KCl 5 mM; MgCl2, 2 mM; HEPES, 10 mM; Glucose, 12 mM; Sucrose, 139 
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mM; pH 7.4). Neurons were then incubated in a cobalt uptake assay buffer (buffer A plus 5 mM 
CoCl2 and 0.5 µM capsaicin) for 8 min at room temperature. Following incubation in the cobalt 
uptake assay buffer, 0.2 % ammonium polysulphide (Sigma) was added and immediately washed 
off using buffer A. Ammonium polysulphide causes the intracellular precipitation of black, 
granular cobalt sulphide in the cytoplasm of neurons due to prior Co+2 ion uptake resulting from 
capsaicin-induced TRPV1 receptor activition. The number of black neurons is thus indicative of 
the percentage of TRPV1 expressing, capsaicin sensitive neurons in a culture. Following the 
assay, the number of black neurons was counted using a bright field microscope and this was 
expressed as a percentage of the total number of neurons counted. 
 
2.12 CHEMICALS 
 Capsaicin, resiniferatoxin, ruthenium red, capsazepine, SB-366791, phorbol dibutyrate 
(PDBu), HYP-3-bradykinin (HYP3BK) and phorbol myristate actetate (PMA) were obtained 
from Sigma (St. Louis, MO). Micromolar and nanomolar dilutions for experiments were made 
by serial dilutions of stock solutions. Chemicals were added to media in the wells just prior to 
plating cells for selection studies. 
2.13 IN-VIVO BEHAVIORAL TESTING 
 All in-vivo tests were performed on adult male Sprague-Dawley rats (200-225 g; Charles 
River, Boston, MA). Four days prior to performing behavioral tests, the animals were 
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subcutaneously injected with 100 µl of vHG, vHDNP (109 pfu/ml) or PBS (sham injection) into 
the plantar surface of the right hind paw. Uninjected animals were included as an additional 
control.   
 Tests for thermal hyperalgesia were performed using a Hargreaves apparatus on a 
platform with a baseline temperature of 25˚C. Each animal was placed on the platform in a 10 
cm x 20 cm plastic container, positioned over a mirror tilted at a 45° angle. All rats were allowed 
to acclimatize to the plastic container and platform for 30 min prior to testing. During each 
evaluation of thermal hyperalgesia, a focused heat source using a light intensity of 30-lumen was 
aimed at the plantar surface of the foot and the time until the animal moved its foot in response 
to the heat measured. Three trials per testing period were made for each animal on both, the right 
and left foot with 1 min rest between each measurement. The average withdrawal time per foot 
was used for statistical comparisons. Data are presented as a ratio of the average time taken for 
withdrawal of the right foot versus the left foot for animals in each group.  
 To test for mechanical allodynia (painful response to an innocuous stimulus) each animal 
was placed in a clear plastic 10 cm x 20 cm container on top of a wire screen.  After a 15-minute 
accommodation period the mechanical threshold was measured by applying a series of von Frey 
hairs to the midplantar surface of each hind paw.  The von Frey hairs are a set of calibrated 
filaments of increasing diameter and stiffness.  As they are pushed against the bottom of the paw, 
animals either retract their foot or not depending on whether or not the pressure from the von 
Frey hair is painful. Withdrawal of the hind paw within 5 seconds was inferred as a positive 
response; no paw withdrawal was inferred as a negative response. The up-down method was 
utilized to determine the 50% gram threshold 68. In this method, a positive response is followed 
by application of the next grade higher filament and a negative response is followed by 
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presentation of the next grade lower filament. Approximately six responses from each animal 
were recorded. An algorithm together with the pattern of responses is used to calculate the 50% 
gram threshold response. 
 
2.14 STATISTICS 
 Graphs for functional assays are based on data from four independent experiments (n=4). 
Error bars for all graphs including graphs for in-vivo behavioral tests are calculated as standard 
deviations. For patch clamp experiments, results are reported as mean ± SEM. For cobalt uptake 
assays, error bars are calculated based on standard deviations from a binomial distribution where 
a neuron with cobalt uptake is indicative of success and a neuron without uptake is indicative of 
failure. Statistical analysis for p values used t-test, 2 tail, and unequal variance. Data were 
considered to be statistically significant if p < 0.05. All images shown are representative results 
following multiple iterations of each experiment. 
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3.0  DESIGN AND DEVELOPMENT OF AN HSV-1 VECTOR-BASED SYSTEM FOR 
THE IDENTIFICATION AND SELECTION OF ION CHANNEL ANTAGONISTS 
3.1 INTRODUCTION 
 The human genome expresses over 400 ion channels involved in almost every vital 
biological process including cardiac, renal and nervous system functions 69. Ion channel 
inhibition is consequently gaining importance as an approach to treat many disorders. Ion 
channel antagonists such as lidocaine (sodium channel antagonist) to treat neuropathic pain, the 
anti-convulsant levetiracetam (N-type calcium channel blocker), the anti-arrhythmic carvedilol 
(L-type calcium channel blocker), anti-cancer agents such as carboxyamidotriazole (non-voltage 
operated calcium channel inhibitor), the anti-emetic ondansetron and numerous others are either 
established drugs or currently undergoing clinical trials 70-75. The need for accelerated drug 
discovery has therefore resulted in high throughput screening (HTS) assays for ion channel 
antagonists 76. Indeed, HTS assays identifying NMDA, AMPA and TRPV1 specific antagonists 
have been recently published 77-80. 
 Recent reports have uncovered the existence of several ion channels that are specifically 
upregulated in nociceptors during the development of chronic inflammatory and neuropathic 
pain states (Fig. 6) 5, 56. The transient receptor potential (TRP) family of ion channels, sodium 
channel subtypes, purigenic receptors (P2X3), voltage gated calcium channels (VGCC) and the 
serotonin ionotropic receptor (5-HT3R) are among the pro-nociceptive receptors, while 
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potassium ion channel subtypes act as modulatory channels during nociception (Fig. 6). 
Although the mechanisms of channel activation are being revealed for many of these receptors, 
pro-nociceptive ion channel-specific antagonists and modulatory gene products are largely 
unknown. It follows that the discovery of specific antagonists or gene products that attenuate 
pro-nociceptive ion channel function may lead to a better understanding of nociceptive 
regulation at the periphery and can provide new drugs and avenues for the treatment of chronic 
pain states. 
 
Figure 6. Pro-nociceptive ion channels. 
The figure depicts ion channels upregulated in chronic pain states that are involved in nociception 
at the periphery of the pain pathway. These channels are directly activated by several components of the 
inflammatory soup such as protons, heat, ATP and bradykinin (From Lee et al, Mol. Cells, Vol.20(3) 315-
324) 
 
              Fluorescence-based high throughput screening (HTS) assays are a mainstay for the 
discovery of molecules that specifically inhibit target ion channels. Current fluorescence based 
HTS assays for antagonists generally rely on a loss of signal following channel activation. This 
strategy results in significant numbers of false positives due to transient signals or signal 
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quenching by the candidate compound 81, 82. As a result, subsequent secondary stage compound 
analyses increase both time and labor requirements. Other HTS assay drawbacks include the use 
of expensive reagents (e.g. FURA-2 in fluorescence based assays), low throughput (e.g. patch 
clamping) or low expression levels (e.g. stably transfected cell based assays). Specifically, assays 
utilizing stably transfected cell lines for cDNA expression exhibit declining expression levels 
with continual in-vitro culture or when applied to high throughput formats 83. This can cause 
ambiguity when interpreting assay results. Given the difficulties with cell based assays, viral 
vector-based transient expression systems offer several advantages such as robustness due to 
ease of handling, high and uniform cDNA expression, excellent control over transgene 
expression achieved by varying parameters of infection and the ability to simultaneously express 
multiple transgenes, a property that can be exploited for ion channels possessing more than one 
type of subunit 83.  
            Replication defective herpes simplex virus-1 (HSV-1) vectors deleted for the essential 
immediate early genes ICP4 and ICP27 have been previously used for therapeutic gene transfer 
44, 45.  This platform has proven useful to evaluate the ability to deliver a variety of anti-
nociceptive gene products in-vivo in animal models of acute, chronic, and neuropathic pain 42. In 
addition, replication defective HSV-1 vectors possess a large transgene capacity, the ability to 
simultaneously express multiple transgenes and an excellent control over transgene expression 
timing by using viral promoters with different kinetics of activation. The current chapter exploits 
these natural properties of HSV-1 viral vectors as a transgene expression tool in order to develop 
an HSV-1 based selection system using the vanilloid receptor as a target ion channel. The 
following paragraphs recap the role of the vanilloid receptor in nociception and the basis for 
HSV-1 vector-based selection.  
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 The vanilloid receptor (transient receptor potential vanilloid 1, TRPV1, formerly known 
as VR1) plays important roles in nociception and physiology, making it an attractive therapeutic 
target for chemical library screens to identify novel receptor antagonists 79, 80. TRPV1 is a 
peripheral pro-nociceptive Ca+2 ion channel belonging to the transient receptor potential (TRP) 
superfamily. TRPV1 is the peripheral sensor of inflammatory mediators such as ATP and 
bradykinin. In addition, TRPV1 is directly activated by heat (43˚C) 25, endovanilloids 
(anandamide) 23, low pH (protons), capsaicin and resiniferatoxin 25. TRPV1 activation through 
this complex array of mechanisms results in the development of the neuronal hyperexcitability 
seen in chronic pain 84. TRPV1 knockout mice exhibit reduced responses to noxious thermal 
stimuli 35, 85, which underscores the contribution of TRPV1 to the pain signaling pathway. Due to 
its vital role in nociception and the likely analgesic benefits of TRPV1 antagonism, this receptor 
was chosen as a model ion channel for developing an HSV-1 vector-based assay to identify 
novel antagonistic compounds.  
 In this chapter, a cell based assay was developed that utilizes herpes simplex virus 1 
(HSV-1) vector expressed TRPV1 channels in which channel activation causes the influx of 
cytotoxic levels of Ca+2 ions into the cell. This Ca+2 influx induces cell death prior to the 
completion of the virus replicative cycle thereby blocking vector replication. TRPV1 antagonists 
in the presence of known receptor agonists reverse the inhibition of HSV-1 virus growth, thus 
allowing the identification of ion channel antagonists by selective vector replication. The HSV-1 
vector may be engineered to co-express gene products such as green fluorescent protein (GFP) 
along with the ion channel. Vector replication resulting from channel antagonism will, in this 
case, cause a gain of fluorescence that can be read by an automated fluorometric plate reader 
(FLIPR). In addition to possessing advantages of a virus-based expression system, as a platform 
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the system is easily adaptable to a variety of ion channels such as the ligand gated TRP, NMDA, 
P2X3 and VGCC receptors. 
3.2 RESULTS 
3.2.1 Vector constructs and Southern Blotting. 
To carry out these studies, two HSV vectors were created, a test vector (vTT) containing 
the TRPV1 gene replacing both copies of the essential immediate early (IE) gene ICP4 and a 
control vector (vHG) in which the ICP4 gene was replaced by an EGFP reporter gene cassette 
(Fig.7, top panel). The recombinant vector backbone is also deleted for the essential IE gene 
ICP27. Deletion of either ICP4 or ICP27 prevents subsequent expression of early or late viral 
genes and provides a platform for gene transfer (Fig. 7, top panel). Vector propagation and 
studies of TRPV1 function expressed from the vector genome were carried out in a 
complementing cell line (7B cells) that supply the ICP4 and ICP27 gene products in-trans.  
 The virus structures were confirmed by Southern blot analysis (Fig 7, bottom panels). All 
DNA digests were separately hybridized to probes for ICP27 (BamH1 to Sac1 fragment), ICP4 
5’ (BamH1 to BglII fragment), thymidine kinase promoter (TKp) (PvuII to BglII fragment) or 
TRPV1 (Asp718 to Not1 cDNA fragment). Results confirm the correct insertion of the TRPV1 
cDNA (TRPV1 probe) replacing EGFP at both ICP4 loci of vHG in vTT (Fig 7). The TKp and 
ICP4 5’ probes confirm that TRPV1 cDNA is under transcriptional control of the viral early TK 
promoter at both ICP4 loci of vTT.  Blots probed with the ICP27 validate the identical deletion 
of ICP27 in both vectors (Fig 7). 
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Figure 7. Genomic representation of the vectors vHG and vTT. 
 The top part of the figure shows schematic representations of the vTT and vHG vectors. Both 
vectors contain deletions of the immediate early (IE) genes, ICP4 and ICP27. In the genome of vHG, an 
HCMV immediate early promoter driving enhanced green fluorescent protein (HCMVp:EGFP cassette) is 
inserted into both ICP4 loci (top panel). In the genome of the vTT vector a TKp:TRPV1 cassette coding 
for the rat TRPV1 receptor, driven by the TK early promoter (TKp:TRPV1) resides in the ICP4 loci (top 
panel). The bottom panels depict Southern blotting to confirm viral genomic structure. vHG, vTT and the 
plasmid pTT used in vTT construction. Viral DNA probed for; 1) the TRPV1 cDNA demonstrates that vHG 
is negative for TRPV1 cDNA. NcoI (1 kb and 0.8 kb bands) and SmaI (1.6kb and 1kb bands) cut TRPV1 
internally. The NcoI digest has 4 kb and 6 kb bands indicative of two TRPV1 copies at the ICP4 loci, 2) 
using the TK promoter (TKp) as a probe confirms vHG and vTT are positive for endogenous TKp. The 
NcoI digest for vTT has two bands, indicating successful insertion of TKp at both ICP4 loci, 3) using the 5’ 
region of ICP4 demonstrates vHG and vTT display band shifts for BamH1 digests, confirming 
replacement of HCMVp:EGFP in vHG with TKp:TRPV1 in vTT at ICP4 loci, 4) Probing for ICP27 flanking 
sequences confirm identical deletions in vectors vTT and vHG. 
 45 
3.2.2 Protein expression profiles for vectors vHG and vTT. 
 TRPV1 was expressed under control of the viral early (E) gene promoter (HSV 
thymidine kinase) and thus is not expressed in non-complementing cells. Expression of TRPV1 
occurs in complementing cells since the virus is able to replicate and thus activate promoters 
with early (E) and late (L) kinetics. This engineered delay in expression of TRPV1 enhances 
virus replication since TRPV1 imparts some toxicity without activation. The EGFP gene was 
placed under control of the HCMV IE promoter that is expressed both in complementing and 
non-complementing cells and is used as a visual indicator of vector transduction. Expression of 
the individual transgenes from the vectors constructed above was confirmed prior to initiating 
functional experiments. Immunostaining for ICP0 in Vero cells at 18 hpi was positive for vHG 
and vTT viruses, confirming expression of ICP0 as an immediate early (IE) gene in both viral 
genomes as expected (Fig. 8). Complementing 7B cells infected with vTT were positive for 
TRPV1 receptor expression by immunofluoresence while the control vHG virus was negative 
indicating exclusive expression of TRPV1 from vTT.  Non-complementing Vero cells infected 
with vTT were negative for TRPV1 at 18 hpi, confirming that TRPV1 driven by the thymidine 
kinase (TK) early (E) promoter is active only during viral replication (Fig. 8).  In 7B cells, the 
vHG virus harbors GFP+ plaques when viewed under fluorescence, while vTT plaquing is GFP-, 
indicative of successful marker transfer in these viruses (Fig. 8). 
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Figure 8. Protein expression profiles for vectors vHG and vTT. 
 The protein expression profiles in complementing 7B and non-complementing Vero cell lines are 
shown for the vector vHG (top three panels) and the vector vTT (bottom four panels). Since the natural 
HSV-1 immediate early (IE) promoter drives ICP0 protein expression, both vectors express ICP0 in non-
complementing Vero cells. EGFP is exclusively expressed by vector vHG. TRPV1 is exclusively 
expressed by vector vTT and is limited to complementing 7B cells indicative of the early thymidine kinase 
(TK) gene promoter used to drive TRPV1 expression (all panels are at 20X magnification) 
 
3.2.3 Functional demonstration of TRPV1 activity. 
 Whole cell electrophysiological recordings of vTT or vHG infected complementing 7B 
cells were done to demonstrate functional activity of the HSV-1 vector-expressed TRPV1 
receptor. Infection of 7B cells was done at a high MOI (MOI of 10) to ensure that all cells in 
culture are infected with at least one virus particle. Figure 9 shows a representative trace of 
electrophysiological recordings from vHG or vTT infected 7B cells. Control vHG infected 7B 
cells did not respond to capsaicin. Capsaicin stimulation of vTT infected 7B cells resulted in 
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large current (nA range) that desensitized with time. The known TRPV1 antagonists, ruthenium 
red (RuR) and diaryl piperazine (NDT9515223, Neurogen) antagonized the vTT-specific 
currents. Table 2 summarizes electrophysiological recordings from vHG or vTT-infected and 
uninfected 7B cells. As seen in Table 2, the pre-incubation of vTT-infected 7B cells with 
bisindolylmaleimide (BIM), a PKC specific inhibitor resulted in significantly lower amplitude 
and rapidly desensitizing capsaicin-induced currents when compared to BIM untreated, vTT-
infected cells. These data demonstrate the functionality of virally expressed TRPV1 in 
complementing Vero cells (7B cell line). 
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Figure 9. Functional demonstration of TRPV1 activation by capsaicin. 
 vHG infected 7B cells do not respond to capsaicin (CAPS) stimulation (upper trace). vTT 
infected 7B cells display a large inward current (9 nA) following stimulation with 0.5 µM capsaicin (CAPS) 
(lower trace). Addition of the TRPV1 antagonist, ruthenium red (RuR - 5 µM) brought the current back to 
baseline. 
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Table 2. Electrophysiological parameters in HSV-1 infected and uninfected 7b cells.  
Parameters of excitability and K+ currents were determined as in methods. Peak outward current 
amplitudes are for currents generated at +60 mV. The numbers of cells measured for each parameter are 
indicated in parentheses. 
 
Level of significance: NS = not significant, ** = p < 0.01, or *** = p < 0.001 
vTT = vector TKp: TRPV1; vHG = vector HCMVp: EGFP ; BIM = PKC inhibitor, bisindolylmaleimide. 
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3.2.4 Demonstration of calcium influx following TRPV1 activation. 
 In order to demonstrate calcium influx through vTT vector-expressed TRPV1, 
intracellular calcium levels were monitored by FURA-2 loading, followed by stimulation of the 
vTT infected 7B cells with capsaicin. At 8 hpi, 3 µM capsaicin resulted in a massive increase of 
intracellular calcium (~900 nM range) in 7B cells infected with vTT virus (Fig. 10A). Ionomycin 
is calcium ionophore that disrupts the cell membrane, thus allowing a free flow of Ca+2 ions into 
the cellular cytoplasm. Ca+2 influx following ionomycin application is therefore indicative of the 
maximum amounts of extracellular Ca+2 ions that can enter a cell. Following the addition of 3 
µM capsacin (CAP), the calcium influx response was sustained and did not further increase with 
5 µM ionomycin (IONO) indicating that the Ca+2 influx with 3 µM CAP was maximal (Fig. 
10A). Addition of 10 mM EGTA caused the signal to return to baseline levels indicating that a 
Ca+2 specific TRPV1 receptor was located on the cell membrane (Fig. 10A). Sub-maximal 
concentration of capsaicin (0.3 µM) caused a smaller response than that observed with 3 µM 
capsaicin (Fig. 10C). This response was further increased after the addition of 5 µM ionomycin 
(Fig. 10C). Since GFP would interfere with FURA-2 measurements, we used the GFP negative 
virus, QOZ as a negative control for intracellular Ca+2 measurements and the demonstration of 
apoptosis. QOZ possesses a similar backbone to vHG, but lacks the HCMVp:EGFP cassette at 
the ICP4 loci. QOZ instead contains an ICP0p-LacZ cassette at the UL41 locus. QOZ infected 
cells displayed a maximal calcium influx in response to 5µM ionomycin, but no effect with 0.3 
or 3µM capsaicin (Fig. 10B and 10D). 
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Figure 10. Demonstration of calcium influx through TRPV1. 
 Intracellular calcium concentrations (Cai, nM) graphed against time (sec) in response to 
stimulation with 3µM (Fig. 9A; 9C) or 0.3 µm (Fig. 9B; 9D) capsaicin (CAP), 5 µM ionomycin (IONO) and 
10 mM EGTA are shown for vTT and QOZ infected cells. 
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3.2.5 Cell death following calcium influx through activated TRPV1. 
 Mitochondrial permeability transition (MPT) is often the first change that occurs during 
the initiation of cell death and is a major component of the apoptotic cascade induced by TRPV1 
activation in several cell types.  Ca+2 overload through activated TRPV1 has been specifically 
and uniquely linked to the development of MPT with the subsequent activation of caspases 86-88. 
In order to demonstrate the development of MPT due to intracellular calcium overload in our 
system, we assayed for MPT and caspase activation following capsaicin exposure in 7B cells 
infected with vTT as described in materials and methods. Following stimulation with 3 µM 
capsaicin for one hour, MPT was specifically seen in vTT infected 7B cells at 12 hpi as 
evidenced by green fluorescent areas corresponding to mitochondria in the perinuclear region of 
dying cells (Fig. 11B is a bright field image of vTT infected 7B cells stimulated with 3 µM 
capsaicin and Fig. 11C is a green fluorescence image of the same field). Cell death and MPT 
were not observed in QOZ infected 7B cells following stimulation with 3 µM capsaicin (Fig. 
11D). The QOZ vector was used as a control for this experiment since the MPT assay is based on 
a green fluorescent readout, thus disallowing the use of a GFP expressing vHG control vector.  In 
addition to the development of MPT, vTT infected cells were positive for activated caspases 
following overnight capsaicin (3 µm) stimulation while QOZ infected 7B cells did not show a 
significant activation of caspases at 16 hpi (personal observation, data not shown). These data 
provide direct evidence for activated TRPV1 triggering Ca+2 overload, leading to MPT, caspase 
activation and the initiation of cell death.  
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Figure 11. Demonstration of MPT and cell death. 
 (A) vTT infected 7B complementing cells without capsaicin. (B) Bright field image of vTT infected 
7B complementing cells incubated with 3 µm capsaicin for 60 min and (C) Flourescent image of the same 
cells loaded with DePsipher dye to detect MPT. (D) Bright field image of vHG (control) infected 7B 
complementing cells incubated with 3 µm capsaicin (all images at 20X magnification, enlarged images 
are at 40X magnification). 
 
3.2.6 TRPV1 activation blocks vector replication. 
 With the influx of cytotoxic levels of calcium into vTT infected cells and the consequent 
initiation of cell death as demonstrated above, it was anticipated that vector expression and the 
subsequent activation of TRPV1 would induce cell death prior to completion of the virus 
replicative cycle, thus blocking virus growth. In the absence of TRPV1 agonists, vector vTT 
replicated less robustly (~0.1 log) than vHG at 24 and 48 hpi, however, the final yield of these 
vectors was similar at 72 hpi. To quantify the effects of TRPV1 activation on viral replication, 
complementing 7B cells were infected at 0.01 PFU/cell and incubated in the presence of 
increasing concentrations (0.1 to 40 µM final) of the TRPV1-specific agonist, capsaicin. To 
display the differences in replication between vHG (control) and vTT (TRPV1 expressing) 
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vectors, the effect of capsaicin concentration was determined at 24, 48 and 72 hpi based on the 
ratio of vHG to vTT virus particle yield (growth ratio, GR).  Significant differences in replication 
between vHG and vTT were observed at concentrations as low as 0.3 µM capsaicin (Fig. 12).  
The greatest GR differential (approximately 500 fold; p < 0.05, n=4) was observed with a 3 µM 
capsaicin concentration at 72 hpi (Fig. 12). In order to demonstrate the relative potency of 
selective replication using multiple TRPV1 agonists, the above experimental procedure was 
repeated with resiniferatoxin (RTX), an ultrapotent TRPV1 agonist. Nanomolar concentrations 
of RTX caused a reduction in vTT viral titers, similar to that seen with ~100 fold higher doses of 
capsaicin at all time points (Fig. 13). The highest observed difference in growth rate (GR = 474; 
p < 0.05, n=4) was seen with 1 µM RTX at 72 hpi (Fig. 13). 
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Figure 12. Effect of capsaicin on vTT viral growth. 
 7B complementing cells were infected with vTT or vHG (control) virus. Infected cells were plated 
in culture media containing increasing doses of capsaicin (0 to 40 μM final). Viral titers determined 
from supernatant media at 24, 48 and 72 hours post-infection (hpi) are plotted against capsaicin 
concentration. Growth ratios, calculated as the ratio of vHG to vTT viral titers at each concentration of 
capsaicin are shown for each graph (* p < 0.05, n = 4). 
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Figure 13. Effect of resiniferatoxin (RTX) on vTT viral growth. 
 7B cells infected with vTT or vHG (control) virus were plated in culture media containing 
increasing doses of resiniferatoxin (0 to 1000 nM final). Viral titers determined from supernatant samples 
are plotted against the RTX concentration at 24, 48 and 72 hours post-infection. Growth ratios for each 
concentration of resiniferatoxin are indicated at the top of each graph (* p < 0.05, n = 4). 
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3.2.7 TRPV1 antagonism rescues vector replication. 
 While TRPV1 activation by capsaicin significantly blocks vector replication, antagonism 
of TRPV1 receptor activation by capsaicin should rescue vector replication. The recovery of 
vector replication following TRPV1 antagonism could then be used as a read-out in a selection 
system to identify additional TRPV1 receptor antagonists from a chemical compound library. In 
order to provide proof of principle data for the above rationale, viral yields were determined for 
infections in the presence of capsaicin alone or in cultures containing both capsaicin and known 
TRPV1 antagonists.  
 To assess non-competitive antagonism of viral growth inhibition, ruthenium red (RuR), a 
known TRPV1 channel pore blocker was added to replication assays along with capsaicin 
(CAP). vHG or vTT vector-infected 7B cells were plated in the presence of 3 µM CAP, 5 µM 
RuR, or 3 µM CAP + 5 µM RuR and samples taken daily for viral titration. Vector replication 
was unaffected by 5 µM RuR alone at 24, 48 and 72 hours post infection (Figs. 14A and 14B). 
The presence of CAP specifically inhibited vTT replication (Fig. 14A) without affecting vHG 
titers. (Fig. 14B). In the presence of both 3 µM CAP and 5 µM RuR, replication of vTT was 
completely restored (p < 0.05, n=4) (Fig. 14A).   
 In order to demonstrate competitive antagonism of TRPV1 activation by capsaicin, 
similar assays were carried out using the known competitive capsaicin antagonist, SB-366791 79. 
Addition of SB-366791 alone (at 1, 5 and 10 µM concentrations) did not affect replication of 
vHG (data not shown) or vTT (Fig. 15B). Addition of both CAP and SB-366791 did not affect 
replication of the control vector, vHG (data not shown). A dose dependent rescue of viral titers 
with 1 µM, 5 µM and 10 µM SB-366791 in the presence of 0.5 µM capsaicin was observed at all 
time points post-infection (p < 0.05, n=4) (Fig. 15A). It should be noted that a similar experiment 
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was performed using another known competitive capsaicin antagonist, capsazepine, however, a 
small and insignificant vTT growth recovery following capsaicin (0.5 µM) stimulation was 
observed with a very high dose of capsazepine (40 µM) at all post-infection time points tested 
(data not shown).  
These data provide proof-of-principle for the growth recovery of a TRPV1 expressing 
HSV-1 vector using known non-competitive and competitive TRPV1 antagonists in the presence 
of the known TRPV1 agonist, capsaicin. 
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Figure 14. vTT growth recovery due to non-competitive antagonism of TRPV1 activation. 
 Growth curves from vTT infected (Graph A) and vHG infected (Graph B) 7B cells at 24, 48 and 
72hours post-infection (hpi) are shown after separate incubation with either nothing (NIL), 3 µM capsaicin 
(CAP), 5 µM Ruthenium Red (RuR), or 5 µM ruthenium red + 3 µM capsaicin (RuR+CAP) (Details in text). 
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Figure 15. vTT growth recovery due to competitive antagonism of TRPV1 activation. 
 Titers from vTT infected 7B cells are represented as growth curves at 24, 48 and 72 hours post-
infection (hpi), after separate incubation with chemicals as follows. Graph A: vTT infection with nothing 
(NIL), 0.5 µM capsaicin (CAP), 1 µM SB-366791 + 0.5 µM capsaicin (SB1+CAP), 5 µM SB-366791 + 0.5 
µM capsaicin (SB5+CAP) and 10 µM SB-366791 + 0.5 µM capsaicin (SB10+CAP); Graph B: vTT 
infection with 1 µM SB-366791 (SB1), 5 µM SB-366791 (SB5) and 10 µM SB-366791 (SB10). See text for 
details.  
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3.2.8 Selection against vTT in mixed infections. 
 The vTT virus described in this study should prove useful in chemical selection assays to 
identify novel antagonists of TRPV1. With this in mind, and to determine the sensitivity of 
capsaicin based genetic selection against TRPV1 activation, mixed infections of 7B cells with 
varying ratios of vTT and vHG viruses were carried out with or without 3 µM capsaicin (0.4 
PFU/cell). Cells were harvested at 72 hpi, after a cytopathic effect was observed and titered. 
Plaques were then counted for each dilution of mixed vTT:vHG infections, and scored as a 
percentage of GFP positive (GFP+ vHG) versus GFP negative (GFP- vTT) plaques. Samples from 
the first passage were then re-passaged in complementing cells with or without 3 µM capsaicin 
(0.4 PFU/cell), followed by rescoring for GFP positive plaques. Figure 16 is a schematic 
depicting the methodology followed for the mixed infection experiments along with 
representative images of the harvests that were titered following serial passages with capsaicin. 
The images are from titers of a 1:200 infection ratio of vTT:vHG. 
 Results are presented in Figure 17 as percent input versus percent output of green 
fluorescent viral plaques. Starting with a 0.005% vHG input (1:20,000 vHG:vTT), 66% after one 
passage and 95% vHG (GFP+) after two passages were obtained in the presence of capsaicin (p < 
0.05, n = 4) (Fig. 17), demonstrating a very effective selective pressure against TRPV1 in the 
presence of capsaicin. Starting with as little as 1:100,000 vHG, cultures were found to contain 
significant proportions (40%) of vHG after two passages in capsaicin (Fig. 17). This data 
demonstrates the sensitivity of using HSV-1 vectors in a capsaicin-based chemical or genetic 
selection strategy to identify TRPV1 antagonists. 
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Figure 16. Selection methodology with capsaicin using mixed virus infections. 
 The figure depicts the method for selection against vTT following mixed infections with the vHG 
vector. The panels at the bottom of the figure show a selection for GFP+ vHG plaques with 3 µM 
capsaicin (selection panels), while GFP- clear vTT plaques outgrow GFP+ vHG plaques in the absence of 
capsaicin (no selection panels). 
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Figure 17. Capsaicin selection sensitivity.  
Mixed infections on 7B cells at indicated ratios (input ratio) of vHG:vTT vectors were passaged with 3 µM 
capsaicin (1st Pass), harvested and titered at 72 hours post-infection (72 hpi). Harvests from 1st passage 
were passaged a second time (2nd Pass) with 3 µM capsaicin, harvested at 72 hpi and titered. The 
relative output of the vHG vector was quantified and is presented as percent output (vHG %). (Note: Error 
bars are small and cannot be seen in this figure; p<0.05, n=4) 
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3.3 DISCUSSION  
The current chapter describes the engineering of a novel herpes simplex virus 1 (HSV-1) 
vector based assay system utilizing selective virus replication as a read-out of channel 
inactivation. In particular, it was shown that agonist-mediated activation of virally over-
expressed TRPV1 in an infected, complementing cell results in the rapid influx of cytotoxic 
amounts of calcium ions into the cytoplasm. Intracellular calcium overload opens mitochondrial 
transition pores, leading to caspase activation and the initiation of an apoptotic cascade within 
the cell. Calcium influx through activated TRPV1 in infected complementing cells causes 
cellular apoptosis before viral replication occurs, ultimately preventing vector replication. 
Lowered viral titers are therefore an indicator of TRPV1 activation, and molecules that 
antagonize TRPV1 activation will conversely rescue virus replication. Replication of vTT is 
substantially suppressed by incubation with capsaicin and viral particles that are able to replicate 
remain sensitive to capsaicin.  
 Initial experiments demonstrated that the TRPV1 expression vector performed as 
expected. Immunostaining of 7b complementing cells infected with vTT was positive for TRPV1 
at 18 hpi and localized to the cellular plasma membrane and cytoplasm. Replication of vTT in 
the absence of agonists was comparable to vHG (control) viral growth at all post-infection time 
points, indicating minimal toxicity due to transgene expression in this system. Patch clamp 
recordings of vTT infected complementing cells demonstrated large currents at all post-infection 
time points tested following the application of 0.5 µM capsaicin, while vHG infected control 
cells did not respond to capsaicin indicating that virally expressed TRPV1 assembled as a 
functional ion channel. The currents were TRPV1 specific since they were blocked by 
application of known TRPV1 antagonists, ruthenium red and diaryl piperazine. Desensitization is 
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a property of ion channels whereby the channel pore closes and stops conducting ions despite the 
agonist being bound to the channel. Desensitization rates of activated TRPV1 are known to slow 
down when the receptor is phosphorylated. This phenomenon is called receptor sensitization. 
Conversely, TRPV1 de-phosphorylation increases desensitization rates. The enhancement or 
attenuation of TRPV1 function thus depends on a dynamic interplay between kinase-mediated 
receptor phosphorylation and phosphatase-mediated de-phosphorylation 15, 89. In the HSV-1 
vector-based TRPV1 expression system, currents desensitized slowly when compared to 
desensitization rates of neuronally expressed TRPV1 65 indicating that the virally expressed 
receptor was maximally phosphorylated. Moreover, the pre-incubation of vTT infected cells with 
BIM, a PKC inhibitor caused significant reductions in current amplitude and accelerated 
desensitization rates following capsaicin application (Table 2). This data points to PKC as the 
kinase that phosphorylates HSV-1 vector-expressed TRPV1 in the experimental system 
described here. It is interesting to note that this increased phosphorylation of TRPV1 mimics a 
pathological state of increased TRPV1 phosphorylation in in-vivo models of neuropathic pain 
and bladder cystitis 65, 90. Activation of the over-expressed TRPV1 receptor after stimulation with 
capsaicin caused a rise in intracellular calcium after addition of 0.3 and 3 µM capsaicin. The 
failure to enhance maximal responses with the calcium ionophore, ionomycin indicated very 
high levels of Ca+2 influx following the application of 3 µM capsaicin. All capsaicin responses 
were sustained and sub-maximal responses could be enhanced with the calcium ionophore 
ionomycin. This suggests that TRPV1 activation in the HSV-1 expression system was 
concentration dependent. Further, the response returned to baseline levels upon application of 
EGTA showing that this effect was caused by calcium ions. These data demonstrated that HSV-1 
vector-expressed TRPV1 functioned as a calcium ion channel.  
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Calcium overload following capsaicin stimulation of TRPV1 has been shown by others to 
cause mitochondrial permeability transition (MPT) followed by caspase activation and apoptosis 
88. Consistent with these observations, vTT infected cells also demonstrated a similar apoptotic 
cascade initiating with MPT following capsaicin treatment, further confirming functionality of 
the HSV-1 based assay system. A source of potential false positives in this assay can be the 
identification of MPT and/or apoptosis inhibitors that may allow vector replication in the 
presence of capsaicin. However, these compounds are also of great interest as a therapeutic 
approach to treat neuronal apoptosis due to spinal cord injury or degenerative disorders 91.  
Moreover, these compounds would be identified by standard second round intracellular calcium 
measurement methods  82. 
The effect of the TRPV1 agonists, capsaicin and resiniferatoxin on vTT replication were 
next studied. Both capsaicin and resiniferatoxin caused a significant (500-fold) and dose 
dependent reduction in vTT replication when compared to the control vHG vector at 72 hpi, 
indicative of a specific effect of these agonists on the TRPV1 receptor. Resiniferatoxin was 
effective in reducing vTT viral titers at nanomolar concentrations (1 nM to 1000 nM final 
concentration) compared to micromolar concentrations (0.1 µM to 40 µM) of capsaicin. This 
dosage phenomenon agreed with other studies in which resiniferatoxin has been shown to be 
several fold more potent than capsaicin as an activator of TRPV1. The non-competitive capsaicin 
antagonist ruthenium red (5 µM) significantly rescued vTT replication in the presence of 3 µM 
capsaicin. Ruthenium red antagonism of capsaicin was almost complete, thus validating the 
HSV-1 vector-based system for selection of chemical antagonists of the TRPV1 receptor.  
Similarly, a concentration dependent reversal of the capsaicin effect with the competitive 
antagonist SB-366791 was found.  
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The vTT virus described in this study could prove useful to express a cDNA library such 
that each virion expresses a unique molecule among which TRPV1 inhibitory cDNA products 
may be selected and captured on the basis of virus replication. With this in mind, and to 
determine the sensitivity of genetic selection against TRPV1 activation, mixed infections 
infections with vTT and a control vHG vector that is negative for TRPV1 expression were 
performed. When one PFU vHG was mixed with 20,000 vTT, a selection for vHG by sequential 
passage in the presence of capsaicin, yielding greater than 95% vHG (GFP+) was achieved. With 
a 1:100,000 vHG:vTT mixture, significant amplification of the selected vHG particle to 
approximately 40 % occurred after two passages in the presence of capsaicin, indicating that the 
selection system was highly sensitive and robust. It can be noted that no obvious TRPV1 mutants 
in vTT were observed during these experiments. This is supported by the fact that a second 
passage in the presence of capsaicin resulted in further selection for the TRPV1 negative and 
GFP+ control vector vHG. The absence of TRPV1 viral mutants allows continuous agonist-based 
selection strategies to be devised.  
 Modulation of ion channel activity has gained recognition as a viable approach to 
treat numerous disorders including epilepsy, cancer and pain 70-75. Significant difficulties remain 
in current assay systems including signal quenching or transient signals for fluorescent readouts, 
resulting in many false positive and false negative outcomes 81, 82. Other assay drawbacks such as 
low throughput, inefficient transgene expression, expensive reagents and inadaptability to 
miniaturized formats reduce assay efficiency and increase screening costs for antagonistic 
compounds. A previous study has addressed the issue of transient signals by using calcium ion 
chelating agents such as BAPTA to increase signal duration following channel activation 81.  
Similarly, assays that employ transfection to express ion channels could be improved using 
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baculovirus-based transient expression systems 83 or other viral platforms such as HSV-1 
vectors.  
  The HSV-1 based assay system described here could be used to identify novel TRPV1 
antagonists from a chemical compound library. The assay can be adapted to a fluorescence read-
out high throughput screen by co-expressing the target ion channel and green fluorescent protein 
(GFP). Virus replication following channel inactivation should result in increased fluorescence 
that can be monitored using a fluorometric imaging plate reader.  Potential advantages of the 
HSV-1 based assay include the ability to simultaneously express multiple genes, efficient 
transgene expression, robustness and cost-effectiveness due to the use of inexpensive reagents. 
Other applications for the system described in this study include identification of novel TRPV1 
antagonists from cDNA, gene-knockout based (e.g. RNAi) or random peptide libraries with 
potential therapeutic applications in the field of pain management as well as providing basic 
scientific understanding of targeted ion channels in chronic pain. 
 69 
4.0  DEVELOPMENT AND CHARACTERIZATION OF HSV-1 VECTOR-
EXPRESSED DOMINANT NEGATIVE PKCε FOR CHRONIC PAIN THERAPY 
4.1 INTRODUCTION 
 Chronic pain occurs as a result of a variety of disorders and is a debilitating condition 
with over 80 million sufferers in the United States (section 1.2.2). Following a resolution of the 
causative pathology, chronic pain states often persist and are accompanied with a distinct set of 
signs and symptoms such as hyperalgesia, allodynia, reduced activity and depression (section 
1.2.1). A recent declaration by the European Federation of the International Association for Pain 
(IASP) chapters states that chronic pain should be recognized as a distinct disease entity and 
treated as such (section 1.2.1). Current analgesics used to treat pain target the nociceptive 
pathway at various levels, but are accompanied by side effects resulting from effects on other 
biological systems (Table 1). An approach to address this problem is to develop a better 
understanding of plastic nociceptive changes that occur during the pathophysiological progress 
of chronic pain and to achieve the targeted inhibition of pro-nociceptive molecules in DRG 
neurons that are the well-known sensory seat of nociception.  
 The vanilloid receptor (transient receptor potential vanilloid 1 or TRPV1, formerly 
known as VR1) has emerged as an important integrator of various inflammatory mediators 
(section 1.2.5) and is likely to be a link in the transition between acute and chronic pain. The 
TRPV1 receptor assembles at the plasma membrane as a tetramer of six transmembrane-
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spanning subunits and is an inward rectifying ion channel that preferentially conducts Ca+2 ions 
through a pore loop between domains 5 and 6 (Fig. 18). TRPV1 is a directly activated by 
protons, pH and heat (43˚C) and is indirectly modulated by several inflammatory mediators like 
ATP and bradykinin via G-protein coupled mechanisms (section 1.2.5). The G-protein coupled 
functional modulation of the TRPV1 and other TRPV channels is achieved through cytoplasmic 
receptor domains possessing consensus sites for the action of kinases and phosphatases (Fig. 18). 
In addition, TRPV1 is subject to unknown modulatory mechanisms by several other molecules 
(Fig. 18) 84. Recent evidence suggests that like many other ion channels, TRPV1 activity is 
controlled, in part, by the phosphorylation state of the receptor 84, 92. TRPV1 activation is 
enhanced following receptor phosphorylation, a phenomenon known as receptor sensitization, 
while de-phosphorylation results in rapid receptor desensitization and a consequent attaenation 
of function. This dynamic interplay between receptor phosphorylation and de-phosphorylation is 
mediated by intracellular kinases and phosphatases 89.  
 TRPV1 sensitization results in an increased activation of the receptor with sub-maximal 
doses of agonists, such that the receptor becomes activated by room temperature, physiological 
pH and lower doses of capsaicin. This hyperactivation or sensitization causes a release of 
calcitonin gene related peptide (CGRP), substance P (SP) and other inflammatory mediators 
from peripheral neuronal terminals 93. CGRP and SP are known to enhance neurogenic 
inflammation in the surrounding tissue 94. A positive-feedback cycle consisting of a loop of 
TRPV1 hyperactivity, the release of SP and CGRP and a consequent increase in the levels of 
inflammatory mediators resulting in further increase in TRPV1 function is thus established, 
creating a pathological microenvironment that results in a self-perpetuating chronic pain state. 
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 Among the kinases that sensitize TRPV1, protein kinase C epsilon (PKCε) has emerged 
as an important pro-nociceptive kinase that phosphorylates TRPV1 at the S502 and S800 
residues. Phosphorylation results in an enhanced in-vitro and in-vivo activation of TRPV1 15, 30. 
A recent study in TRPV1 knockout mice demonstrated significant reductions in nocisposive 
behavior following stimulation with the PKC specific activator, phorbol myristate acetate (PMA) 
39, while another study has reported reduced pain behavior in response to heat application in 
PKCε knockout mice 38. Additional reports have shown that PKCε is specifically activated 
downstream of the bradykinin receptor 2 in nociceptive neurons, thus providing a molecular link 
between bradykinin (BK) and nociception 95, 96. Finally, in-vitro electrophysiological recordings 
in neurons demonstrate an enhanced TRPV1 function in neurons following pre-incubation with 
BK, mediated by PKC 27. Taken together, these results have uncovered a unique nociceptive 
pathway in which PKCε is activated downstream of the bradykinin receptor 2 and 
phosphorylates TRPV1 resulting in the sensation of pain 96. Thus, the inhibition of PKCε is a 
potential strategy to break this positive feedback cycle and consequently attenuate TRPV1 
function in-vivo. 
The herpes simplex virus-1 (HSV-1) virus is neurotropic and therefore ideally suited as a 
delivery vehicle for the targeted expression of therapeutic transgene products in nociceptive 
neurons. Replication defective HSV-1 vectors have been previously used as a gene delivery 
vehicle to attenuate pain in several animal models (sections 1.2.7 and 1.2.8). In the current 
chapter, the neurotropism of replication defective HSV-1 mutant vectors is exploited as a means 
to attenuate TRPV1 function at the periphery of the nociceptive pathway by the targeted delivery 
of a dominant negative form of PKCε to DRG neurons. Chapter 4 describes the design, 
development and characterization of an HSV-1 vector engineered to express a dominant negative 
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form of PKCε and its use to attenuate TRPV1 function in-vitro and in-vivo. This study may 
provide future avenues for the development of analgesics for chronic pain that exert their effects 
via the targeted inhibition of pro-nociceptive gene products at the periphery of the nociceptive 
pathway. 
 
Figure 18. Subunit structure of the TRPV1 receptor. 
 The figure shows a TRPV1 receptor subunit structure. Putative sites for the action of 
several modulatory gene products are highlighted. The PDZ domain (green oval) is a scaffolding 
domain that links components of signaling complexes. The ankyrin binding site (blue oval) may 
also perform a scaffolding function by tethering the receptor to intracellular cytoskeletal elements. 
The kinase domains (red diamonds) for protein kinase C (PKC) and protein kinase A (PKA) are 
present at the T144 (PKC), S502 (PKC and PKA), T704 (PKC and PKA) and S800 (PKC) 
residues of TRPV1. The PI3-kinase (PI3K) and SH2 domains (purple diamonds) are putative sites 
for phosphorylation by PI3K and tyrosine kinase repectively and may play a role in receptor 
sensitization. The calmodulin binding domain (pink rectangle) plays a role in receptor 
desensitization by recruiting calcineurin to de-phosphorylate TRPV1 in a calcium dependent 
manner. (Figure modified from Pedersen et al, Cell Calcium 38 (2005), 233-252) 
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4.2 RESULTS 
4.2.1 Vector constructs. 
 The two vectors used throughout this study are called vHDNP and vHG. vHDNP is the 
experimental vector (vector HCMVp:Dominant Negative PKCε)  containing a dominant 
negative PKCε (DNP) construct fused to green fluorescent protein (GFP) at the UL41 locus of a 
replication defective HSV-1 vector deleted for ICP27 and both copies of ICP4 (Fig. 19A). DNP 
and vHDNP were engineered as described in materials and methods (section 2.1.1). Figure 19A 
shows the full-length PKCε structure and the deletions in the DNP construct, driven by an 
HCMV IE promoter. Prior to starting experiments, the UL41 locus of vector vHDNP was PCR 
amplified and the correct insertion of the HCMVp:DNP transgene cassette was confirmed by 
sequencing. Successful DNP insertion into vHDNP was also confirmed by Southern blotting 
using a PKCε cDNA probe (BglII to SalI fragment) (data not shown). The vector, vHG shown in 
figure 19A was used as a control for all experiments. vHG has been described in materials and 
methods (section 2.1.2) and in chapter 3. 
4.2.2 Dominant negative PKCε (DNP) protein expression by vHDNP. 
 vHDNP-mediated expression of DNP was first confirmed by Western blotting. vHDNP 
infected 7B cells (MOI of 3 at 16 hpi) were positive for a 47 KDa band when probed with a GFP 
antibody, while vHG infected 7B cells (MOI of 3 at 16 hpi) were positive for a 27 KDa GFP 
band (Fig. 19B). The 20 KDa shift between vHDNP-infected and vHG-infected 7B cells when 
probed with the same GFP antibody corresponded with the size of the DNP construct without a 
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GFP fusion, thus indicating successful vHDNP-mediated expression of the DNP transgene fused 
to GFP in complementing 7B cells. A similar result was obtained using vHDNP or vHG-
transduced non-complementing Vero and U2OS cells (Fig. 19B). Expression in non-
complementing cell lines indicated that the DNP transgene in vHDNP was driven by an HCMV 
immediate early promoter. 
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Figure 19. Dominant negative PKCε (DNP) structure and transgene expression. 
(A) Full length PKCε with sub-domain functions and phosphorylation sites are shown (top). The 
dominant negative PKCε (DNP) + GFP fusion construct along with vector (vHDNP and vHG) genomic 
structures are also shown. (B) Western blots to confirm DNP transgene expression from vHDNP or vHG 
in the indicated cell lines are shown. See text for details. 
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4.2.3 Demonstration of vHDNP-expressed dominant negative PKCε (DNP) translocation 
in U2OS and Vero cells. 
 Following a confirmation of vector-mediated DNP expression in complementing and 
non-complementing cell lines, the functionality of vector-expressed DNP was studied in U2OS 
and Vero cells. PKC-specific activators like phorbol myristate actetate (PMA) bind to the 
regulatory domain of PKCs resulting in kinase translocation to the plasma membrane. Membrane 
translocation is an indirect indicator of kinase function as the PKCs mediate most of their 
signaling functions following localization near surface receptors. Since the PMA binding sub-
domain (C1a) is retained in the DNP construct, it was anticipated that the stimulation of vHDNP-
transduced cells with PMA would result in the membrane translocation of DNP. Translocation 
can be visualized by live cell imaging with green fluorescence emitted by the DNP construct.  
To study the functionality of the DNP construct, vHDNP vector-transduced non-
complementing Vero and U2OS cells (MOI of 3 at 16 hpi) were visualized for DNP expression 
by live cell imaging using a fluorescent microscope. Following transduction with vHDNP, Vero 
and U2OS cells displayed a distinct perinuclear localization of the DNP transgene product prior 
to PMA stimulation (Fig. 20A,C). 5 µM PMA was added to the media and cells were 
immediately imaged as described in materials and methods (section 2.6). PMA stimulation 
caused DNP to completely translocate to the plasma membrane in Vero and U2OS cell (Fig. 
20B,D). Translocated DNP appeared to localize in specific structures morphologically 
resembling microvilli in Vero cells, while DNP uniformly translocated to the plasma membrane 
in U2OS cells. This data confirmed functionality of the vHDNP vector-expressed dominant 
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negative PKCε in non-complementing cell lines and encouraged further studies of DNP function 
in DRG neurons. 
   
Figure 20. PMA-induced functional translocation of vHDNP vector-expressed dominant 
negative PKCε (DNP) in Vero and U2OS cells. 
The figure shows the following vHDNP vector-transduced cells: A) Vero cells without PMA, B) 
Same field of Vero cells at 3 min 41 sec after 5 µM PMA addition, C) U2OS cells without PMA and D) 
Same field of U2OS cells at 3 min 16 sec after 5 µM PMA addition. Panel A shows a perinuclear 
localization of vHDNP-expressed dominant negative PKCε in all Vero. Panel C shows a perinuclear as 
well as cytoplasmic localization of DNP in U2OS cells prior to PMA stimulation. The intranuclear 
fluorescence in these cells is an optical artefact. 
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4.2.4 vHDNP-expressed dominant negative PKCε (DNP) inhibits endogenous PKCε 
translocation in DRG neurons. 
 Following the functional demonstration of vector-expressed DNP in Vero and U2OS 
cells, the ability of DNP to inhibit the translocation of endogenous PKCε in adult rat DRG 
neurons was examined. The assay utilized for this purpose is shown in Figure 21 and is based on 
the rationale that following activation with a PKC activator in vHDNP-transduced neurons, DNP 
will translocate to the plasma membrane and consequently inhibit the translocation of 
endogenous PKCε. vHG-transduced control neurons will by contrast, display a normal 
translocation of endogenous PKCε along with a cytoplasmic localization of GFP, thus 
confirming the ability of DNP to inhibit endogenous PKCε in DRG neurons.  
 vHG or vHDNP-transduced neurons were stimulated with 5 µM of the PKC-specific 
activator, phorbol myristate acetate (PDBu) for 2 min, fixed and immunostained for endogenous 
PKCε. Immunostaining was done with a primary antibody that recognizes the C-terminal domain 
of PKCε and is consequently specific for endogenous PKCε (see section 2.5 for details).  A red 
fluorescent Cy3 secondary antibody was used to visualize endogenous PKCε staining. 
Unstimulated vHG and vHDNP vector-transduced neurons immunostained for endogenous 
PKCε were used as a negative control for this experiment. Figure 22 shows representative 
images of vector-transduced neurons with and without PDBu stimulation. As seen in Figure 22, 
unstimulated vHG-transduced neurons displayed a diffuse localization of vector-expressed GFP 
(Fig. 22A), while DNP localized to perinuclear regions in unstimulated vHDNP-transduced 
neurons (Fig. 22G). Unstimulated vHG and vHDNP-transduced neurons also showed a diffuse 
localization of endogenous PKCε (Fig. 22 B,H). Following stimulation with 5 µM PDBu, 
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endogenous PKCε translocated to the plasma membrane in vHG-transduced neurons (Fig. 22E), 
while the localization of GFP in these neurons remained unaffected (Fig. 22D). Following 
stimulation with 5 µM PDBu, DNP completely translocated to the plasma membrane in vHDNP-
transduced neurons (Fig. 22J) while the translocation of endogenous PKCε in these neurons was 
almost completely inhibited (Fig. 22K). Merged images show a significant co-localization of 
DNP and endogenous PKCε (yellow-orange color) at perinuclear regions of unstimulated 
vHDNP-transduced neurons (Fig. 22I). DNP and endogenous PKCε did not significantly co-
localize in neurons following stimulation with PDBu (Fig. 22L). Finally, the GFP in merged 
images of unstimulated and PDBu stimulated vHG-transduced neurons did not co-localize with 
endogenous PKCε (Fig. 22 C,F). These data clearly demonstrate that the dominant negative 
PKCε (DNP) construct expressed by the vHDNP vector prevented the translocation of 
endogenous PKCε in adult rat DRG neurons. 
 It should be noted that all experiments performed in DRG neurons utilized PDBu as the 
PKC activator in place of PMA. The reason for this is that PMA, unlike PDBu is known to 
directly bind to and activate the TRPV1 receptor (Bhave et al, PNAS, 2003;100(21):12480-85). 
The use of PDBu thus prevented possible sources of error arising from PMA-mediated direct 
activation of TRPV1 in later experiments.   
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Figure 21.  Assay rationale for the demonstration of DNP function in neurons. 
 The figure is a schematic of the assay rationale to demonstrate the DNP-mediated inhibition of 
endogenous PKCε in neurons. vHG or vHDNP vector-transduced neurons are either left unstimulated (No 
PDBu) or are stimulated with 5 µM PDBu (+PDBu) and immunostained for endogenous PKCε (red). An 
unstimulated (No PDBu) vHG or vHDNP vector-transduced neuron (shown at the top) will display a 
diffuse localization of DNP or GFP (green speckles) and endogenous PKCε (red speckles). Following 
PDBu stimulation (+PDBu), a vHG-transduced neuron (bottom left neuron) will show a complete 
translocation of endogenous PKCε to the plasma membrane, while the GFP protein will remain 
unaffected. PDBu stimulation (+PDBu) of a vHDNP-transduced neuron (bottom right neuron) will by 
contrast display a complete plasma membrane translocation of the DNP product (green) and an inhibition 
of endogenous PKCε translocation, thus confirming the functional inhibition of endogenous neuronal 
PKCε by DNP. 
 81 
 
 
Figure 22. vHDNP-mediated inhibition of endogenous PKCε in adult rat DRG neurons. 
 vHG (panels A to F) or vHDNP (panels G to L) transduced neurons were fixed and 
immunostained for endogenous PKCε (red fluorescence) (panels B,E,H,K). Projections of multiplanar 
stacked images for each transduced neuron (approx. 30 µm diameter) before (No PDBu) and after 
(+PDBu) stimulation with PDBu are shown. Merged images show that GFP expressed from vHG does not 
affect PDBu induced endogenous PKCε translocation (panel F), while DNP expressed from the vHDNP-
transduced neuron almost completely inhibits PDBu-induced endogenous PKCε translocation (Panel L). 
Vectors used to transduce the neurons and PDBu treatments for each neuron and indicated at the left of 
the figure. See text (section 4.2.4) for a detailed explanation. 
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4.2.5 vHDNP-expressed dominant negative PKCε (DNP) inhibits TRPV1 activity in rat 
DRG neurons. 
 With the demonstration of dominant negative PKCε (DNP)-mediated inhibition of 
endogenous PKCε translocation to the plasma membrane of neurons, it was anticipated that the 
DNP transgene product might attenuate TRPV1 activity since the vanilloid receptor function is 
coupled to PKCε-mediated receptor phosphorylation (section 4.1). The cobalt uptake assay 
provides a means for the quick and efficient assay of TRPV1 activity in a large number of DRG 
neurons in culture 97. With this in mind and to determine the effect of DNP on TRPV1 activity 
in-vitro, cobalt uptake assays were done to examine adult rat DRG neuronal TRPV1 activity in 
vHDNP-transduced cells. Non-transduced and vHG-transduced neurons were used as controls 
for this experiment. Cobalt uptake assays were performed as described in materials and methods 
(section 2.11). The transduction of neurons with vHG and vHDNP vectors was performed as 
described in section 2.2.5 in order to ensure that 100% of the neurons in culture were transduced 
with HSV-1 vectors.  
Figure 23A depicts the rationale for cobalt uptake assays. Vector-transduced or non-
transduced DRG neurons in culture are incubated for 8 min with a cobalt chloride (CoCl) buffer 
containing capsaicin (0.5 µM). Capsaicin-mediated activation of neuronal TRPV1 receptors will 
cause Co+2 ions to flux into neurons that express functional TRPV1 receptors at the plasma 
membrane. Co+2 is then precipitated with ammonium polysulphide that reacts with the 
intracellular Co+2 ions in TRPV1 positive cells forming a black precipitate of cobalt sulphide 
(CoS). Thus, black intracellular precipitates are an indirect indicator of neurons expressing 
functional TRPV1 receptors. These neurons can then be counted with a light microscope and are 
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presented as a percentage of capsaicin sensitive neurons. Figure 23 also shows a representative 
image of a TRPV1 negative neuron with no cobalt uptake (Fig. 23B) and representative images 
of non-transduced, vHG-transduced and vHDNP-transduced capsaicin sensitive neurons with 
cobalt uptake (Fig. 23 C,D,E). It should be noted that the cobalt precipitate in vHDNP-
transduced neurons was lighter than that seen in non-transduced or vHG-transduced neurons. 
These neurons were counted as capsaicin sensitive.  
Figure 24 summarizes results of cobalt uptake assays. The type of neuron (x-axis: non-
transduced or vHG-transduced or vHDNP-transduced) is plotted against the percentage of 
capsaicin sensitive neurons by cobalt uptake (y-axis). The numbers of neurons counted for each 
group are shown in parentheses. As seen in the graph (Fig. 24), approximately 44% of non-
transduced neurons were capsaicin sensitive, while 33% of vHG-transduced neurons 
demonstrated capsaicin sensitivity. By contrast, only 12% of the vHDNP-transduced neurons 
were capsaicin sensitive. The result was significant when compared with the number of capsaicin 
sensitive vHG-transduced neurons (p<0.001). This data demonstrates the HSV-1 vector 
expressed dominant negative PKCε (DNP)-mediated in-vitro attenutation of TRPV1 activity in 
response to capsaicin stimulation in adult rat DRG neurons. 
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Figure 23. Rationale for cobalt uptake assay. 
 (A) The rationale for cobalt uptake assay to determine the number of capsaicin sensitive 
neurons in culture is shown. Non-transduced or vector-transduced neurons are stimulated with a 
buffer containing cobalt chrloride (CoCl) and 0.5 µM capsaicin for 8 min. Intracellular Co+2 ions 
in TRPV1 positive neurons are treated with ammonium polysulphide (NH4S) to form a black 
cobalt sulphide precipitate. These capsaicin sensitive black neurons can be counted under a 
microscope. Representative images of (B) a neuron with no cobalt uptake, (C) a non-transduced 
neuron with cobalt uptake, (D) a vHG-transduced neuron with cobalt uptake and, (E) a vHDNP-
transduced neuron with cobalt uptake are shown. 
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Figure 24. Demonstration of vHDNP-mediated inhibition of TRPV1 activity by cobalt 
uptake assays.  
 The graph plots the percentage of capsaicin sensitive neurons (%) counted by cobalt uptake (y-
axis) for groups of non-transduced, vHG-transduced or vHDNP-tranduced neurons (x-axis). 44% of non-
transduced and 33% of vHG-transduced neurons were capsaicin sensitive. The number of capsaicin 
sensitive neurons was significantly reduced to 12% following transduction with vHDNP (p<0.001). The 
number of neurons counted for each group are indicated in parantheses.   
 
4.2.6 vHDNP-expressed dominant negative PKCε (DNP) inhibits and modulates TRPV1 
currents in rat DRG neurons. 
 Cobalt uptake assays demonstrated an en-masse, quantitative reduction in TRPV1 
activity mediated by HSV-1 vector-expressed dominant negative PKCε (DNP). This encouraged 
qualitative studies addressing the ability of DNP to modulate TRPV1 currents in single neurons. 
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With this in mind, whole cell electrophysiological recordings of capsaicin-induced currents were 
performed in vHG and vHDNP vector-transduced neurons.  
 For these studies, adult rat DRG neurons in culture were transduced with either vHG or 
vHDNP as described in materials and methods (section 2.2.5). Putative nociceptive neurons were 
chosen based on their diameter (small to medium diameter of 30 to 40 µm), an elongated 
morphology and the emission of green fluorescence by the neuron following vector transduction. 
The elongated small to medium diameter neurons neurons in non-transduced control DRG 
cultures were found to be capsaicin sensitive approximately 50 percent of the time. Figure 25 
A,B,C and D show representative bright field and fluorescent images of vHG- and vHDNP-
transduced neurons that were chosen for whole cell electrophysiology. Gigaohm-seal whole-cell 
recordings of capsaicin-induced currents were done in these neurons as described in materials 
and methods (section 2.7). 
 Figure 26A is a representative recording of capsaicin-induced currents obtained from 
vHG-transduced neurons. As seen in Figure 26A, the application of capsaicin (CAPS, 0.5 µM) 
caused an inward TRPV1-mediated current (500 pA amplitude) in these neurons. This current 
was significantly enhanced by addition of the bradykinin receptor 2-specific agonist, HYP-3-
bradykinin (HYP3BK, 5 µM). Addition of the non-specific PKC activator, PDBu (5 µM) did not 
further enhance the TRPV1 current, while an application of the PKC-specific inhibitor 
bisindolylmaleimide (BIM, 5 µM) accelerated the TRPV1 current desensitization rates. The 
current was completely antagonized and returned to baseline values following application of the 
TRPV1-specific agonist, diaryl piperazine or NDT9515223 (TRPV1 Ant, 5 µM). This indicated 
that the current enhancement by HYP3BK was specific to the TRPV1 receptor. It should be 
noted that the addition of PDBu alone without prior incubation with HYP3BK caused an 
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enhancement of the TRPV1 current in other recordings of vHG-transduced neurons, indicating 
that PDBu-induced current enhancement was obliterated when HYP3BK was used.  
 Figure 26B is a representative recording of capsaicin-induced currents in vHDNP 
transduced neurons. As seen in the figure, in contrast to recordings in vHG-transduced neurons, 
vHDNP-transduced neurons consistently displayed diminished (50 pA amplitude), rapidly 
desensitizing currents following application of capsaicin (CAPS, 0.5 µM). This current was not 
enhanced following the application of HYP3BK. The application of 5 µM PDBu consistently 
caused a slow onset drift like enhancement of TRPV1 currents. This effect was antagonized by 
the application of 5 µM BIM. Incubation with the TRPV1 anatgonist diaryl piperazine (TRPV1 
Ant, 5 µM) completely returned the currents to baseline values indicating that the drift current 
caused by PDBu was TRPV1 specific. 
 Figure 27 A,B and C summarize the findings from electrophysiological studies. As seen 
in Figure 27A, vHDNP caused a significant reduction in capsaicin-induced current amplitudes in 
DRG neurons when compared with non-transduced (control) or vHG-transduced neurons 
(p<0.01).  vHDNP transduction also resulted in significantly accelerated desensitization rates of 
capsaicin currents (p<0.01) when compared with non-transduced and vHG-transduced controls 
(Fig. 27B). The time taken for current amplitudes to peak following PDBu stimulation was 
significantly reduced in vHDNP-transduced neurons when compared with non-transduced or 
vHG-transduced controls (p<0.001), indicating that the PKC translocation and consequent 
TRPV1 phosphorylation in vHDNP-transduced neurons was inefficient when compared with 
controls. Figure 28 is a graph showing comparisons of desensitization rates and effects of PDBu 
application between vHDNP-transduced and non-transduced neurons. As seen in the figure, 
desensitization rates of vHDNP-transduced neurons were ~10-fold faster that the rate at which 
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the non-transduced neuron desensitized. In addition to these findings, a significant reduction in 
the number of capsaicin-reponsive vHDNP-transduced neurons was observed in comparison with 
controls (data not shown). Taken together, these results demonstrate that HSV-1 vector-
expressed DNP qualitatively inhibits and modulates the current responses to capsaicin in rat 
DRG neurons and results in an overall in-vitro attenuation of neuronal TRPV1 function.  
 
 
 
Figure 25. Neurons chosen for whole cell electrophysiological recordings.  
 The figure shows representative images of adult rat DRG neurons chosen for whole cell 
electrophysiology. Putative nociceptive neurons that were between 30 to 40 µm in diameter and emitted 
green fluorescence as a result of GFP or DNP transgene expression following vector transduction were 
chosen for recordings of capsaicin currents. The panels in this figure show a bright field image of vHG-
transduced neurons (panel A), a fluorescent image of the same field displaying vHG-transduced neurons 
with green fluorescence from the GFP transgene product (panel B), a bright field image of vHDNP-
transduced neurons (panel C), and a fluorescent image of the same field displaying vHDNP-transduced 
neurons with green fluorescence from the DNP transgene product. 
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Figure 26. Whole cell capsaicin currents in vHG and vHDNP-transduced neurons.  
 Representative recordings of capsaicin currents in vHG- and vHDNP-transduced neurons are 
shown. A) Capsacin currents in vHG-transduced neurons were enhanced by a bradykinin receptor 2 
agonist (HYP3BK, 5 µM). Application of 5µM PDBu did not further enhance the current. Addition of the 
PKC inhibitor, bisindolylmaleimide (BIM, 5µM) partially blocked the current. The current was completely 
antagonized by a TRPV1-specific antagonist (TRPV1 Antag). B) vHDNP1-transduced neurons displayed 
diminished capsaicin (CAP) currents that were not enhanced by HYP3BK. 5 µM PDBu caused a drift 
current that was partially antagonized by 5µM BIM. TRPV1 antagonist (TRPV1 Ant) completely returned 
the current to baseline values. Scales showing time (sec) and current amplitude (pA) are indicated for 
each recording.  
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Figure 27. Summary of vHDNP-mediated TRPV1 current inhibition.  
 A) vHDNP-transduced neurons displayed significantly diminished (p<0.01) current amplitudes 
when compared with vHG-transduced or non-transduced (control) neurons. B) vHDNP transduction of 
neurons resulted in faster desensitization rates of capsaicin-induced TRPV1 currents when compared 
with vHG-transduced or non-transduced (control) neurons. C) PDBu stimulation of vHDNP-transduced 
neurons resulted in a significantly increased time for the capsaicin currents to reach peak amplitude when 
compared with vHG-transduced or non-transduced (control) neurons (p<0.001). The number of neurons 
measured for each parameter are indicated in parantheses. 
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Figure 28.Comparison of desensitization rates and PDBu effects between non-transduced and 
vHDNP-transduced neurons.  
   The graph depicts a representative recording of the capsaicin (CAPS) current response in a non-
transduced neuron in blue. The capsaicin current in this neuron desensitizes over a period of several 
seconds. PDBu application greatly enhances current amplitude and results in a non-desensitizing current. In 
contrast, vHDNP-transduced neurons display small currents in response to capsaicin (CAPS) (black trace). 
The currents show a drift with PDBu application that can be antagonized with a TRPV1-Antagonist. Also 
shown is a 3X magnification of the same vHDNP-transduced neuronal recording (larger black trace). As seen, 
the desensitization rate is significantly faster in the vHDNP-transduced neuron (approximately 20 sec) when 
compared with the non-transduced neuron (approximately 150 sec). 
4.2.7 vHDNP-expressed dominant negative PKCε (DNP) inhibits TRPV1 function in-vivo. 
 Experiments performed so far revealed a vHDNP-mediated inhibition of endogenous 
PKCε translocation in adult rat DRG neurons. This was accompanied by quantitative and 
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qualitative reductions in the TRPV1 activity of cultured DRG neurons as shown by results from 
cobalt uptake assays and electrophysiological recordings. Together, these results confirm the 
ability of HSV-1 vector-expressed dominant negative PKCε to inhibit endogenous PKCε 
function in rat DRG neurons and thereby attenuate TRPV1 function in-vitro. Following the in-
vitro demonstration of TRPV1 inhibition by vHDNP, the next step was to examine the in-vivo 
attenuation of TRPV1 function by vHDNP. Since the TRPV1 receptor is a known sensor of 
noxious heat (43˚C), in-vivo tests examined nociceptive responses of vector-inoculated rats 
following the application of an intense heat source. 
For in-vivo experiments, young adult male Sprague-Dawley rats were subcutaneously 
injected with 100 µl of vHG, vHDNP (109 pfu/ml) or PBS (sham injection) into the plantar 
surface of the right hind paw. Uninjected animals were included as an additional control. 
Animals were placed on a temperature-controlled platform and tested for thermal hyperalgesia 
by the application of an intense light source to the footpad. A focused heat source (30-lumen 
light intensity) was aimed at the plantar surface of the foot and the time until the animal moved 
its foot in response to the heat was measured. Figure 29A shows the paw withdrawal latency 
times (y-axis) presented as ratios of the average time taken for withdrawal of the right foot 
versus the left foot for animals in each group (x-axis). As seen in the figure, the ratio for paw 
withdrawal latency in the uninoculated and PBS injected control rats was around 1, while the 
ratio in vHG-inoculated rats was 0.85. When compared with the vHG-inoculated group, rats 
inoculated with the vHDNP vector displayed a significantly increased paw withdrawal ratio of 
1.25 (p<0.05). 
Immediately following the tests for thermal hyperalgesia, the rats were also tested for 
mechanical allodynia using von Frey hair stimulation as described in materials and methods 
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(section 2.13). Figure 29B summarizes findings from tests for mechanical allodynia where data 
are presented as a ratio of 50% gram threshold responses between right and left paws for each 
group. As seen in the figure, there were no significant differences in the ratios of 50% gram 
threshold responses between the three groups of rats.  
These data indicate a subtle inhibitory effect of vHDNP on the sensory responses of rats 
to noxious heat stimuli. 
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 Figure 29. In-vivo effects of vHDNP in adult rats. 
 Vector-inoculated, sham injected and uninfected rats were examined for painful behaviors in 
response to heat (thermal hyperalgesia) and innocuous mechanical stimuli (mechanical allodynia). A) 
Data are presented as the ratio of right to left paw withdrawal latencies (y-axis) for each group of rat (x-
axis). A significant difference was observed in the ratios of paw withdrawal latencies between the vHG 
and vHDNP vector-inoculated rats. B) The graph plots the right to left paw ratios of 50% gram threshold 
responses (y-axis) for each group of rat (x-axis). No significant differences were observed between the 
three groups of rats. The number of rats for each group are indicated in parantheses for each graph. 
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4.3 DISCUSSION  
 Protein kinase C epsilon (PKCε) is a pro-nociceptive molecule that potentiates TRPV1 
activation in DRG neurons, leading to the development of a chronic pain state. The targeted 
inhibition of PKCε function in nociceptive afferent neurons therefore represents a novel strategy 
to attenuate TRPV1 function in order to prevent the development of chronic pain. In this chapter, 
the neurotropism of herpes simplex viral vectors have been exploited for the targeted delivery of 
a dominant negative PKCε  (DNP) transgene product to DRG neurons. The design, development 
and functional effects of HSV-1 vector-expressed DNP on neuronal TRPV1 receptor function in-
vitro and in-vivo have been described.  
 Initial experiments demonstrated the successful expression of dominant negative PKCε 
(DNP) from the HSV-1 vector, vHDNP. The PKC-specific activator, PMA caused a 
translocation of DNP to the plasma membrane of vHDNP-transduced Vero and U2OS cells, thus 
confirming the functionality of this transgene product.  
 Interestingly, DNP translocated to specific regions resembling microvilli in Vero cells, 
while the translocation in U2OS cells occurred uniformly along the plasma membrane. The C2 
sub-domain of PKCε is known to confer signaling specificity to this isozyme by binding to the 
receptor for activated kinases (RACK2) at the plasma membrane 98. However, the DNP construct 
used in this study is deleted for the C2 domain and still translocates to specific structures in Vero 
cells, suggesting that there may be other unknown cell specific determinants of subcellular 
localization and the consequent signaling specificity of PKCε. Indeed, studies have shown that 
specific subcellular localization of PKCε can be mediated by the pseudosubstrate (PS) region or 
the variable 3 (V3) region, both of which are retained in the DNP construct 99-102. Prior to PMA-
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mediated enzyme activation, the HSV-1 vector-expressed DNP construct localized to perinuclear 
regions of U2OS, Vero and neuronal cells while perinuclear localization of DNP was not 
observed in Vero and U2OS cells transfected with a DNP expressing plasmid (p41HDNP). 
Figure 30 shows vector vHDNP-transduced Vero cells with a distinct perinuclear localization of 
the DNP transgene product in all cells (Fig. 30A), while plasmid p41HDNP transfected Vero 
cells display a uniform and non-specific localization of DNP in all the cells (Fig. 30B). This 
points to the idea that the HSV-1 vector may mediate perinuclear DNP localization in these cells. 
In support of this theory, a recent study has shown that PKC isoenzymes localize to areas 
surrounding the nuclear lamina in HSV-1 infected HEp-2 cells 103.  
 
 
 
Figure 30. Subcellular localization of DNP in vHDNP-transduced and p41HDNP plasmid-
transfected Vero cells. 
 A) vHDNP vector-transduced cells show a distinct perinuclear localization of DNP in all cells, and 
B) DNP displays is uniformly localized throughout the cells following transfection with a DNP expressing 
plasmid, p41HDNP (Images are at 40X magnification). 
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Following the confirmation of vHDNP vector-mediated DNP expression and 
functionality, the ability of DNP to inhibit the translocation of endogenous PKCε in cultured 
DRG neurons was examined. Results from in-vitro experiments in PDBu-stimulated neurons 
transduced with vHDNP showed that following activation, DNP translocated to the neuronal 
plasma membrane and inhibited the translocation of endogenous PKCε. The DNP translocation 
in neurons occurred uniformly across the plasma membrane and was much faster than that 
observed in Vero and U2OS cells. The addition of 1 µM cytochalasin 30 min prior to PDBu 
activation in neurons resulted in a reduction in the rate of DNP translocation (personal 
observation, data not shown). Since cytochalasin disrupts the actin cytoskeleton, this observation 
suggests that DNP translocation may occur via binding to the actin cytokeleton. This theory 
agrees with the fact that PKCε possesses a unique actin-binding site in the regulatory domain 
that is retained in the DNP construct 104. 
As mentioned earlier, PKCε is known to phosphorylate and potentiate TRPV1 receptor 
function in a variety of painful inflammatory and neuropathic conditions, making PKCε 
inhibition a potential strategy to treat chronic pain states. The demonstration of vector-expressed 
DNP functionality in Vero and U2OS cells and the DNP-mediated inhibition of endogenous 
PKCε in cultured DRG neurons encouraged further studies to evaluate the effects of vector-
expressed DNP on TRPV1 receptor activity in cultured DRG neurons. The cobalt uptake assay 
allows a quick evaluation of ion channel activity in a large number of DRG neurons in culture 
and was therefore used to determine the effect of DNP on TRPV1 activity. Since PKCε is an 
indirect downstream potentiator, and not a direct activator of TRPV1, the assays were expected 
to reveal comparatively normal levels of TRPV1 activity in vHDNP-transduced neurons 
following an activation with the direct receptor agonist, capsaicin. However, surprisingly, 
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vHDNP-transduced neurons showed a marked reduction in capsaicin-induced TRPV1 activity 
when compared with non-transduced or vHG-transduced control neurons. Moreover, vHDNP-
transduced neurons that were positive for cobalt uptake showed a lighter staining when 
compared with non-transduced and vHG-transduced neurons. This observation meant that either 
the TRPV1 receptor was desensitizing rapidly due to the inhibition of endogenous PKCε or that 
the expression of functional TRPV1 receptors at the neuronal plasma membrane was reduced. In 
order to dissect out these possibilities, qualitative whole cell electrophysiological recordings of 
capsaicin-induced TRPV1 currents in vHDNP-transduced neurons were performed. Cobalt 
uptake studies in vHG-transduced neurons displayed near normal TRPV1 activity in response to 
capsaicin stimulation and were therefore used as a control for these experiments. The following 
paragraphs will describe molecular mechanisms thought to be responsible for the various effects 
of capsaicin currents in control vHG-transduced neurons followed by a discussion of the 
capsaicin current recordings in vHDNP-tranduced neurons. 
vHG-transduced neurons demonstrated capsaicin-induced currents of a normal amplitude. 
Addition of the bradykinin receptor 2 (BK2R) specific agonist, HYP-3-bradykinin (HYP3BK) 
enhanced the capsaicin current. The increase in TRPV1 function and current amplitudes 
following stimulation of the BK2R receptor has been previously reported in several studies 
described in the introduction of chapter 4. Briefly, BK2R is a G-protein coupled receptor that, 
when stimulated results in the downstream activation of PKCε. Activated PKCε translocates to 
the membrane and phosphorylates the TRPV1 receptor, resulting in a potentiation of TRPV1 
function and the consequent enhancement of current amplitude. This enhancement of current 
with HYP3BK could not be further enhanced with the addition of a non-specific PKC activator, 
PDBu, indicating that PKCε is likely to be the major isoform that phosphorylates and enhances 
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TRPV1 function in cultured DRG neurons. This result contradicts a previous study showing that 
PKCα and not PKCε is the isoform coupled to the enhancement of TRPV1 function in DRG 
neurons 105. As mentioned in the introduction of this chapter, the dynamic interplay between 
receptor phosphorylation and de-phosphorylation by kinases and phosphatases is thought to 
govern TRPV1 function 89. The constitutive activity of kinases within the neuron may be 
responsible for both receptor sensitization as well as the ability of TRPV1 to remain in an 
optimal capsaicin responsive configuration. The inhibition of kinases is therefore likely to 
attenuate capsaicin responses in TRPV1 due to a comparatively greater constitutive activity of 
phosphatases. The phosphatase mediating this effect is likely to be calcineurin because of the 
presence of a calmodulin binding site at the C-terminal domain of TRPV1. In accord with this 
theory, the addition of a non-specific PKC inhibitor, bisindolylmaleimide (BIM) resulted in an 
acceleration of TRPV1 current desensitization due to the unchecked activity of endogenous 
neuronal phosphatases in the cell. Finally, the addition of a TRPV1 specific agonist returned the 
current to baseline levels indicating that the effects of HYP3BK and BIM were due to a TRPV1-
mediated current.  
In stark contrast to the vHG-transduced neuronal capsaicin currents, the capsaicin 
responsiveness in vHDNP-transduced neurons was significantly reduced. This correlated with 
the reduction in capsaicin sensitive neurons seen by cobalt uptake. vHDNP-transduced neurons 
that responded to capsaicin consistently demonstrated diminished, rapidly desensitizing currents. 
These results indicate that the inhibition of endogenous PKCε in neurons severely diminishes the 
ability of capsaicin to activate TRPV1. To my knowledge, this phenomenon has not been 
previously reported and it is likely that PKC-mediated phosphorylation may be a requirement for 
capsaicin-induced TRPV1 activation. Moreover, TRPV1 phosphorylation by Ca+2/Calmodulin 
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dependent kinase was shown to be a requirement for TRPV1 activation by capsaicin and 
resiniferatoxin in a previous study 106. It is therefore likely that variations in the combinations of 
receptor phosphorylation and de-phosphorylation sites regulate vanilloid receptor sensitivity to 
different agonists. 
In contrast to vHG-transduced neurons, the addition of HYP3BK following the onset of 
capsaicin-induced currents consistently failed to enhance current amplitude, thus confirming the 
complete inhibition of endogenous PKCε activation downstream of bradykinin receptor 2 
(BK2R). 
The addition of PDBu following HYP3BK in vHDNP-transduced neurons consistently 
caused a slow onset drift-like current that was antagonized by the addition of the non-specific 
PKC inhibitor, BIM. Addition of a TRPV1 antagonist returned the current to baseline levels 
indicating that a TRPV1-specific current caused the PDBu-induced drift. Mechanistically, this 
may translate into either the inefficient phosphorylation of TRPV1 by other isoforms or a 
delayed onset, inefficient phosphorylation of TRPV1 by endogenous PKCε. Since PKCε was the 
major isoform contributing to the enhancement of capsaicin-induced TRPV1 currents as 
described earlier, the later case of inefficient receptor phosphorylation by endogenous PKCε is 
more likely.  
Taken together, findings from electrophysiological recordings show that following 
transduction of neurons, HSV-1 vector-expressed DNP severely inhibits capsaicin-induced 
TRPV1 currents and that this inhibition is accompanied by significant changes in endogenous 
PKC activation profiles. 
Following the successful domonstration of the vHDNP-mediated inhibition of TRPV1 
activity in cultured DRG neurons, the effects of vHDNP on in-vivo nociceptive behaviors in 
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adult rats was examined. Since the TRPV1 receptor is a known direct sensor of noxious heat 
(43˚C), the paw withdrawal responses of rats following an application of noxious heat to the rat 
footpad was used as a behavioral model. A subtle but significant effect of delayed withdrawal 
responses was observed in vHDNP-inoculated rats when compared with uninoculated and vHG-
inoculated rats. The absence of a complete loss of heat sensitivity is in agreement with the fact 
that several other TRP receptors, expressed nociceptive neurons directly sense heat 20 and also 
with the idea that PKCε may act exclusively through the TRPV1 receptor to cause pain 39. 
Moreover, mice without TRPV1 and TRPV2 receptors have been shown to possess normal heat 
responses, suggesting that there may be other unknown heat sensing receptors in nociceptive 
neurons 107. The results obtained in this chapter thus suggest that a specific knockdown of 
TRPV1 function in-vivo may have been achieved using the vHDNP vector. This can be 
beneficial if the inhibition of PKCε is to be used as a strategy to treat pain, since acute pain 
responses to heat are protective and must be preserved. 
 It should be noted that several pieces of data in this study point toward a unique 
mechanism that might involve the inadequate assembly of a TRPV1-bradykinin receptor 2 
(BK2R)-PKCε signaling complex in neurons transduced with vHDNP. These data are 
summarized as follows: A drastic reduction of the capsaicin current amplitudes in vHDNP-
transduced along with rapid current desensitization was observed by combined results from 
cobalt uptake studies and electrophysiological recordings. This fits with the idea that a reduced 
number of surface TRPV1 receptors, when activated, will cause a reduction in whole cell current 
amplitudes or a quantitative fall in the Co+2 ions that flux into the cell. In addition, HYP3BK 
failed to cause any enhancement of current, while PDBU stimulation resulted in an inefficient 
TRPV1 current enhancement. This can be interpreted as a complete absence of the bradykinin 2 
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receptor at the cell surface. The consequently inefficient anchoring and phosphorylation 
mechanism for PKC following stimulation with PDBu in vHDNP-transduced neurons is read as 
slow, inefficient drift-like currents by electrophysiology. Finally, the number of capsaicin 
responsive vHDNP-transduced neurons were greatly reduced when compared with controls. This 
points towards an overall reduction in the assembly of functional TRPV1 receptors on the plasma 
membrane of DNP expressing DRG neurons. The theory of a possible disassembly of the 
TRPV1-BK2R-PKC signaling complex following an inhibition of PKCε function in nociceptive 
neurons is supported by studies of TRP signaling complexes in drosophila. These studies show 
that eye-specific PKC null mutant flies possess an inadequate assembly of the TRP signaling 
complex with the consequent loss of visual function 108. A series of studies by the same group 
have also shown that the TRP receptor assembles in drosophila photoreceptors as a large 
signaling complex called the transducisome which consists of a multivalent scaffolding protein 
called INAD that tethers TRP receptors to phospholipase C and PKC subunits. Further, it was 
shown that a disruption of any of these transducisome components including PKC caused a 
mislocalization of the complex and a consequent loss of function 109-111. Indeed, the association 
of ion channels with signaling complexes in neurons is a field of growing interest 112. With the 
plethora of recent literature showing that TRP receptors and other ion channels associate with 
large signaling complexes, it is likely that the DNP product used in this study mediates the 
inhibition of TRPV1 by a disruption of the signaling complex associated with this receptor. 
Support for this viewpoint can also be gained a study showing that PKC is involved in the 
trafficking of TRPV1 receptor in neurons 113. Although I have not addressed the aspect of 
TRPV1-PKC assembly in my dissertation, this thesis provides future avenues and tools for 
research into the area of TRPV1 transducisome assembly in DRG neurons.  
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5.0  SUMMARY AND CONCLUSIONS  
Chronic pain is a complex process caused by peripheral plastic changes in nociceptive 
neurons. These changes are largely mediated by the activation of receptors that detect the release 
of inflammatory mediators from damaged tissue at the periphery of the nociceptive pathway. 
Recent research has uncovered the existence of several ion channels and pro-nociceptive 
molecules that are specifically upregulated in chronic pain states. Among these, the vanilloid 
receptor (TRPV1) is an important calcium ion channel activated by several noxious stimuli and 
protein kinase C epsilon (PKCε) is a pro-nociceptive kinase that potentiates and enhances 
TRPV1 function. Following activation, TRPV1 initiates plastic changes in neurons that 
ultimately result in a chronic pain state. The inhibition of TRPV1 function can therefore be an 
effective strategy to treat chronic pain. This dissertation focuses on the development of methods 
and tools that can be used to identify inhibitors of the TRPV1 receptor in chapter three, while an 
inhibition of TRPV1 function by the HSV-1 vector-mediated expression of dominant negative 
PKCε is described in chapter four.   
In chapter three, a selection system using the rationale of selective HSV-1 vector 
replication following the antagonism of vector-expressed receptor function was developed. The 
TRPV1 receptor was used as a model gene to develop this system. Salient features of this system 
are as follows: 
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1) The HSV-1 vector-expressed TRPV1 receptor was activated by capsaicin, 
resulting in an influx of cytotoxic levels of calcium ions into the cell. 
2) Calcium influx following TRPV1 activation caused cell death prior to the 
completion of the HSV-1 replicative cycle. This resulted in a fall of viral titers 
as an indirect effect of TRPV1 activation. 
3) Antagonism of TRPV1 activation with known receptor inhibitors reversed this 
blockage of viral replication thus providing a model system whereby ion 
channel inhibitors can be identified by virtue of their ability to cause a 
recovery in HSV-1 viral growth. 
4) The system was highly sensitive to capsaicin selection since it was possible to 
select for one particle of a GFP expressing vector among 100,000 background 
viral particles that expressed TRPV1. 
In conclusion, the HSV-1 vector-based selection system described in chapter three is a 
powerful platform system that can be applied to other ion channels involved in nociception. The 
system can also be used in cDNA and RNAi library screens to identify novel biological products 
that inhibit ion channel function. The identification of nociceptive ion channel inhibitors and 
modulatory gene products can provide novel treatments for chronic pain and help develop a 
better understanding of regulatory mechanisms in nociception. 
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Chapter four of this dissertation describes the use of a dominant negative PKCε construct 
to inhibit TRPV1 function in-vitro and in-vivo. Salient findings from this study are summarized 
below: 
1) HSV-1 vector expressed dominant negative PKCε (DNP) was functional and 
translocated to the membrane in Vero and U2OS cells following activation 
with the known PKC activator, PMA. 
2) Following stimulation with the known PKC activator, PDBu, HSV-1 vector-
expressed DNP translocated to the plasma membrane of DRG neurons in 
culture and as a result, inhibited the functional translocation of endogenous 
PKCε.  
3) Neurons transduced with HSV-1 vectors expressing DNP displayed marked 
reductions in capsaicin sensitivity and also showed several changes in the 
responses of capsaicin currents to the PKC activators, PDBu and HYP3BK 
when compared with controls. This indicated that vector-expressed DNP 
inhibits TRPV1 function in-vitro. 
4) Behavioral studies in rats demonstrated that HSV-1 vector-expressed DNP 
caused a small reduction in nociceptive responses to noxious heat, thus 
indicating a knockdown of TRPV1 function in-vivo. 
In conclusion, chapter four demonstrates the use of HSV-1 vectors as a valuable 
expression tool to inhibit TRPV1 function in-vitro and in-vivo. In addition, mechanisms for the 
inhibition of TRPV1 function by HSV-1 expressed DNP were partially dissected, providing 
several avenues for future research in this area.  
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